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INVESTIGATING THE INFLUENCE OF LANGERHANS CELLS ON KERATINOCYTE
PROLIFERATIVE RESPONSE TO CHEMICAL AND ULTRAVIOLET B (UVB) EXPOSURE.
Authors: Kseniya Golubets, Renata Filler, Julia Lewis, Debra S. Smith, Scott J.
Roberts, Douglas Brash, Wengeng Zhang, Marcus Bosenberg, William Damsky,
Robert Tigelaar, and Michael Girardi
Initially Girardi lab demonstrated that LC facilitate chemical carcinogenesis by
showing lower levels of proliferation in LC-deficient (Langerin-diptheria toxin A
transgenic) mice relative to LC-intact littermate controls. Thus, we sought to explore the
breadth of potential influences of LC on keratinocyte responses (hypertrophy, apoptosis,
and clonal expansion) in two classic models of carcinogenesis (chemical and UVB), by
using immunohistochemical (IHC) and immunofluorescent (IF) methods of cell
identification. At baseline, LC-deficient compared to LC-intact mouse skin showed
comparable proliferation levels as measured by Ki-67 IHC (13.6±2.6 vs 12.7±2.8 Ki-67+
cells, NS) and epidermal thickness (7.9±1.8 vs 6.9±2.8 µm, NS). After a single
application of mutagen DMBA, followed by repeated applications of tumor promoter TPA
(x 5.5 wks), LC-depleted skin showed smaller increase in epidermal proliferation (31.5 ±
7.7 vs 25.7 ± 7.4 # Ki-67+ cells, P=0.007) and minimal epidermal thickness (59.2 ± 28.4
vs 25.8 ± 8.9 µm, P<0.0001), as compared to LC-intact skin. There was a similar trend
of decreased epidermal proliferation and decreased minimal epidermal hypertrophy in
LC-depleted (Lang-DTA) skin after chronic TPA-alone (x 4 wks, P=0.0002 and
P<0.0001, respectively), or DMBA-alone application (P=0.0001 and P<0.0292,
respectively). To address the potential influence of LC on acute UVB-induced
keratinocyte damage, mice were irradiated with a single dose of 3,360J/m2. There was a
trend toward increased epidermal apoptosis (cleaved caspase-3, P< 0.0001 and
sunburn cells). Chronic low-dose UVB (500-1500 J/m2, 5d/wk x 5-9wks) induced mutant
keratinocyte islands over-expressing p53 (CM5) in both LC-intact and LC-deficient skin,
with a statistical trend towards greater levels within LC-intact skin. After 5 and 9 weeks
of chronic UVB exposure Lang-DTA mouse skin, compared to NLC, had a smaller
number of mutated clones per mm2 (P=0.0489 and P=0.004, respectively). After 5 weeks
of chronic UVB followed by 3 weeks of no UVB (and DT injection at weeks 6, 7 and 8),
there was a smaller number of mutant clones per mm2 in Lang-DTR mouse skin versus
NLC (P< 0.0001). For this group, statistical significance was also reached for mean
number of mutated clones/mm2 per group in Lang-DTR vs NLC mice (P=0.0106). After 5
weeks of chronic UVB, ‘replacement’ LC are associated with mutant clones in Lang-DTA
mice, as compared to areas without clones (P< 0.0001). Statistical significance was also
reached for mean density per mouse (P=0.0106). A similar association was seen in NLC
mice after 5 weeks of chronic UVB, where LC were associated with mutant clones in
NLC mouse skin as compared to areas without clones (P= 0.0047). After chronic UVB,
GL3+ dendritic cell numbers were decreased, but still present, in Lang-DTA and NLC
mice, many located within or near hair follicles and some seen interacting with LC. After
5 weeks of chronic UVB, Lang-DTA mice have approximately 12 times less langerin+ DC
compared to NLC mouse skin. In summary, LC exert diverse, measurable influences on
chemically induced keratinocyte proliferation and acute and chronic UVB-induced
keratinocyte apoptosis.

	
  

	
  

3	
  

ACKNOWLEDGEMENTS
To Dr. Michael Girardi, who has been an inspirational mentor and a role model.
Thank you for your guidance, creativity and positive thinking throughout the year.
To Renata Filler, Julia Lewis and Scott Roberts for always being the helping
hand in everything. I would not have been able to accomplish much without your
immense knowledge and generous support. To Badri Modi, who shared a part of
the burden of countless hours of cell counting on ImageJ!
To Dr. Robert Tigelaar and Dr. Marcus Bosenberg for being part of my thesis
committee for your many great intellectual contributions.
To Dr. Marcus Bosenberg, whose guidance in analyzing murine keratinocytes
and sunburn cells could not have been done without. To Bill Damsky who
generously helped with starting many protocols from scratch. To Maciej Maniecki
for all his generous help with my SID poster and scanning slides.
To Vinny Klump, who was an amazing teacher in IHC and IF techniques and for
teaching me how to cut frozen sections. Thank you to the rest of the
Dermatopathology family, who have done so much for us.
To Dr. Jennifer McNiff who was so generous to allow us to use the fluorescent
microscope.
To the office of student research (Mae Geter, Donna Carranzo, Dr. John Forrest)
for answering millions of questions and always being available to help.
To my mom and Rudy for their unlimited love and support. To Juliana Tolles for
the helpful discussions about statistical analysis. To all my friends who are
always there for me.

	
  

	
  

4	
  

TABLE OF CONTENTS
Abstract ................................................................................................................. 2
Acknowledgements ............................................................................................... 3
Introduction............................................................................................................ 5
LC Characteristics and Other Langerin+ DC
The LC Paradigm
LC Ablation Models
LC as APC
LC Role in CHS: a prototype assay of antigen presentation and T cell
induction
LC Role in Tumorigenesis
Chemical carcinogenesis and the potential tumor-promoting role of LC
UVR and UVR-Damaged Keratinocytes: Mutated Clones
Apoptotic Signals In Keratinocytes
Sunburn Cells
Protective Role of Apoptosis in Cancer
Conflicting Role Of Apoptosis in Cancer
LC after UVB irradiation
LC Role In Immune Suppression
Statement of Purpose.......................................................................................... 35
Material and Methods .......................................................................................... 36
Results
Chemical .................................................................................................... 48
Acute UVB .................................................................................................. 50
Chronic UVB ............................................................................................... 53
Discussion ........................................................................................................... 61
References .......................................................................................................... 71
Figures............................................................................................................... 103

	
  

	
  

5	
  

INTRODUCTION
Langerhans cells (LC) are dendritic cells (DC) of the epidermis whose exact
functions are not completely understood. LC constitute a subset of DC that reside
in the stratified squamous epidermal layer of the skin, as well as in the mucosal
epithelia lining the ocular, oral and vaginal surfaces (1). LC were first described
by Paul Langerhans in 1868 in Berlin, as dendritic cells in the human epidermis
and were mistaken for nerve cells. Not until 1985 were LC accepted as part of
the DC family by Schuler and Steinman (2). In 1992 Jacques Banchereau and
Christophe Caux were the first to generate LC with Birbeck granules from human
hematopoietic progenitor cells (CD34+ cells) (3), a cell line model still used widely
today. In 1999 Sem Saeland and Jenny Valladeau identified the langerin /CD207
marker, which facilitated further study of LC biology. Miriam Merad in 2002
revealed that in the steady-state Langerhans cells remained in the epidermis for
virtually the entire life, and that they slowly renew themselves in situ by
proliferation (4). In 2003 Allan et al. revealed the surprising findings that LC are
not the only APC for pathogen-presentation in vivo, as they were not involved in
herpes viral presentation (5). Just when it seemed that generation of mouse
models around 2005-2006 to selectively deplete LC in vivo would clarify LC role
in immune regulation, they created even more controversy by showing
heterogeneous findings in contact hypersensitivity (CHS) reactions. In 2007 it
was shown that langerin was no longer a unique marker of epidermal LC, but
was also shared with several other DC of the dermis, lymphoid tissues, and
various other organs of the body outside the skin.
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LC CHARACTERISTICS AND OTHER LANGERIN+ DC
In humans, the LC population can be characterized as co-expression of
langerin (a C-type lectin receptor), CD1a (which plays a role in presentation of
lipid microbial antigens), major histocompatibility complex (MHC) class-II, Ecadherin (which mediates LC attachment to keratinocytes), the membrane
ATPase (CD39), the chemokine receptor CCR6, the adhesion molecule Ep-CAM,
and the integrin CD11b (6-8). LC in steady state are known to be very long-lived
and re-populate within the epidermis. However, during inflammation (hapten
sensitization, tape stripping, UV irradiation), monocyte-derived progenitors from
the blood (characterized by high expression of the Gr-1 molecule) enter the LCdepleted epidermis in a CCR2-dependent way and give rise to LC (9).
Although langerin was initially described as a specific and exclusive
marker for LC (10,11), it was recently revealed that other DC outside the
epidermis can also express langerin (12-15). Over the years and through the use
of LC ablating models, it had become apparent that langerin+ DC exist in
epithelia outside the skin’s epidermis and constitute various functional DC
subsets. Originally, it was presumed that the recently observed langerin+ DC in
the dermis (dDC) were just migratory epidermal LC. However, new evidence has
revealed the former to be a separate subtype of dermal dendritic cells (dDC)
(13,14). Langerin+ dDC are CD11blo, CD103+, Ep-CAM/CD326lo, while LC are
CD11bhi, CD103 -, Ep-CAMhi (1,16). Moreover, dDC seem to originate from
different precursors and have different characteristics. dDC seem to come from a
radio-sensitive blood-derived precursor recruited to the dermis, while LC are
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radioresistant and in steady state conditions originate from stem cells in the
epidermis and seem to have a significantly lower BrdU incorporation (14). LC are
dependent on TGF- β, colony-stimulating factor (M-CSF)⁄CSF-1 and interleukin
(IL)-34, while langerin+ dDC are dependent on the cytokine Flt3 ligand for
development ((1).
The majority of blood CD8+ DC in the thymus, spleen, cutaneous lymph
nodes (LN) and mesenteric LN are langerin+ as well (17-19), and can be
distinguished from dermal langerin+ DC (dDC), by the former being CD8+ and
CD11chigh (1). Langerin+ DC have identified in various organs of the body,
including the bronchial epithelia and arterioles of the lung (20), throughout the GI
tract, and in the cornea.

THE LC PARADIGM
The classically accepted ‘LC paradigm,’ a term coined by Wilson and
Villadangos in 2004 (21), included three key functions of LC established mainly
from in vitro studies. Firstly, immature LC residing in steady state were regarded
as highly specialized in antigen uptake and ideally placed in skin to survey the
environment with their dendrites (22). Second, LC transport antigen to skin
draining LN to present to naïve T cells that recognize rare epitopes. To do this,
LC are activated by cytokines and pathogen products (23,24), down-regulating Ecadherin and expressing CCR7, a chemokine receptor that homes LC to T cell
areas in the LN. Third, during migration LC ‘maturate’ into a stimulatory
phenotype,
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histocompatibility complex (MHC)-class I/II and co-stimulatory molecules are
upregulated. This LC paradigm was extended to explain peripheral selftolerance. LC were presumed to be the key players in presenting self-antigen in
both chronically inflammatory (25,26) and steady-state environments (27,28). DC
(presumably LC) have been shown to transport epidermally restricted antigens
(29), present them via the endocytic molecule CD205 (30), and establish CD4
and CD8 T cell tolerance (31), which may occur via induction of regulatory T cells
(32,33), with involvement of E-cadherin (34).
However, with the advent of increasing in vivo studies in LC research, more
and more studies suggest alternative possibilities regarding the relative
contributions of skin DC (LC and dDC) in cross- presentation of skin-derived
antigens, T cell priming, viral immunity, and contact hypersensitivity (CHS). Early
in vivo reports had hinted at LC role in CHS, by demonstrating close apposition
of mononuclear cells to LC in contact allergic reactions (35) and adoptive
transfers of haptenized LC in naïve animals (36,37), but this role was questioned
with the development of LC ablating models.

LC ABLATION MODELS
Langerin is a C-type lectin that induces the formation of Birbeck granules
(10) and is specific to LC in the epidermis, dermis and lymphoid tissues (as well
as other organs as discussed earlier). Because its ablation does not interfere
with LC function (38), it has been employed as a useful target to deplete LC in in
vivo mouse models by three international groups: French, Dutch, and American.
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These transgenic mouse models either use diphtheria toxin (DT) subunit A (DTA)
to constitutively delete LC from birth or the DT receptor (DTR) to induce LC
ablation with DT injection. The following discussion of these models was covered
by Dan Kaplan and others in their 2008 review (39).
DT is a heterodimeric protein that inserts its A subunit by binding the B
subunit to heparin-binding EGF-like growth factor (HB-EGF) precursor on the
surface of mammalian cells (39). Once inside the cell, DTA works by inhibiting
protein biosynthesis and inducing cell death. Inserting a human HB-EGF
precursor (DTR) into a rodent LC sensitizes the cells to DT, resulting in selective
ablation with exogenous injection of DT. Since the rodent homologue of HB-EGF
precursor does not bind to the B subunit of DT, DTA is not internalized by rodent
cells and remain resistant to exogenous DT injection (40).
The inducible ablation models (initially developed by the French and Dutch
groups) (19,41) were generated knock-in mice of the human DTR into the
langerin locus (Langerin–DTR–EGFP). The Dutch group targeted a DTR–EGFP
cassette into the second exon of the langerin gene (41). The French group
generated two separate lines in which either an IRES–EGFP or an IRES–DTR–
EGFP cassette was knocked-in to the sixth exon, in the 30-untranslated region of
langerin (19).
Thus, systemic intraperitoneal (i.p.) injection of DT depletes epidermal LC
within 24-48 hours, which start to repopulate in 2-4 weeks. However, whereas
epidermal LC are still absent 10 days after depletion with DT, langerin+ dDC start
to repopulate by that time (12). Similar kinetic analyses were performed in the
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Clausen group Lang-DTR mice (42). Forty-eight hours after DT injection, no LC
and no dDC could be detected, but by day 10, around 22% of the dDCs were
found, but no LC. Fourteen days after injection, around 25% of the dDCs had
reappeared and a few LC could be visualized, as previously reported by others
(15,41). dDC reach approximately 50% of their steady-state levels by week 2
post DT injection (39). Of note, a subset of CD8+ DC, which is found throughout
the secondary lymphoid tissues (LN, spleen and thymus), also express langerin
and are ablated after DT administration (19).
Alternatively, the American group generated bacterial artificial chromosome
(BAC)-transgenic mice by inserting DTA (not DTR) into the 3’-untranslated region
of the langerin gene contained within a 70-kb fragment of human genomic BAC
DNA (43). Unlike Langerin–DTR–EGFP (Lang-DTR) mice, where all langerin+
DC are ablated, in Lang-DTA mice only epidermal LC are absent. This is
probably related to altered regulation of expression of the human langerin
promoter in Lang-DTA mice compared to the endogenous mouse promoter in
Lang-DTR mice (39). The Kaplan group later developed the inducible DTR-model
as well (44).

LC AS APC:
LC have long been thought of as potent initiators of skin immunity.
Consisting of only 2% of the epidermal population (22), LC manage to cover
more than 25% of the skin’s surface, made possible by laying their disc-like
bodies parallel to epidermal surface and extending a network of dendrites (45).
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Interestingly, the reduction in LC density per unit area in sun-exposed sites is
reported to be compensated for by an increase in the mean cell volume (45).
Using their dendrites (22) LC probe their environment for antigens – exogenous
and endogenous- to present to the adaptive immune system. Their strategic
location in the epidermis and evidence of langerin+ DC localizing to well
vascularized marginal zones in the spleen (46) gives them the ideal opportunity
to take up antigens trafficking through these locations (47). LC can be induced by
topical haptens and perturbations to the skin to undergo phenotypical and
morphological changes, and migrate to draining lymph nodes carrying
melanosomes and apoptotic bodies (48). LC can cross-present antigens (49),
induce expansion of memory CD8+ T cells and are very efficient at priming or
inducing CD4+ T cells to secrete Th2 cell- type cytokines, i.e. IL-4, IL-5, and IL-13
(50). LC have also been shown to promote cytotoxic responses against infectious
antigens and tumor cells (49).
Most of our earlier knowledge about dermal DC and LC phenotype and
function was obtained through the study of these cells cultured in vitro from
CD34+ hematopoietic progenitor cell or blood-derived monocytes (51,52), and
had shown LC to be potent APC. Epidermal LC were found to be able to present
exogenous peptides to T cells (53). Often LC are referred to as prototypic
immature dendritic cells, stemming from early reports showing freshly isolated LC
as weak stimulators of primary T cell proliferation, but in tissue culture these
murine epidermal LC have been shown to mature into potent immunostimulatory
DC in vitro (54).
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With more advanced technologies of deriving LC from skin explants and

freshly isolated from epidermal and dermal suspensions, it has become more
evident that a heterogeneous population of DC inhabits the skin and that LC role
as APC may be redundant. Analysis using global transcriptional profiling of skinderived CD1a+ dDC and CD1a+ LC in resting, non-inflamed skin, found these two
DC to be two truly separate DC subsets and not a functional continuum of one
subset as thought earlier (8). Moreover, a whole shift in the ‘LC paradigm’ has
been occurring, as more evidence is presented on LC role in silencing immune
responses against self-antigens and innocuous environmental antigens (55). LC
may contribute to immune tolerance, alluding to a possible intrinsic nature to
maintain homeostasis of self-tolerance and limit autoimmune reactions.
In murine studies, it has been noted that LC are slower to arrive at draining
lymph nodes than Langerin-negative DC, raising the possibility of an immune
regulatory role for LC when they enter the lymph nodes (56). During steady state,
LC and other DC are thought to take up self-antigen and melanin and migrate to
draining LN (4,29,57). However, one recent report comparing gene analysis of
LC and their dDC counterparts, found that the population of migrating LC may
account for a small fraction of the dermis- derived CD1a+ DC and thus may play a
smaller role in steady state antigen presentation that previously thought (8). They
found that LC residing in the epidermis under steady-state conditions exhibit a
non-migratory and non-stimulatory phenotype. Steady state LC expressed
molecules involved in cell adhesion (i.e. E- cadherin, ICAM-3, and epidermal
surface antigen) or are involved in DC retention such as (junctional adhesion
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molecules and CD47), but lacking expression of molecules involved in DC
migration (i.e. CCR7). Notably, ligation of CD47 (also known as integrinassociated protein), has been demonstrated to regulate LC maturation and
migration, resulting in the suppression of LC function, resulting in decreased T
cell priming and consequent immune suppression (58).
Furthermore, Sangoets et al. showed that under steady state conditions LC
exhibit a non-stimulatory profile, expressing relatively low levels of co-stimulatory
and adhesion molecules (i.e. CD80, CD40, and CD54) or pro-inflammatory
cytokines and cytokine receptors and do not express T cell stimulation molecules
(i.e. 4-1BB and CD30L). The non-T cell stimulatory profile of LC is further
illustrated by the expression of CD43 (also known as leukosialin), a glycoprotein
that is only expressed on immature DC and implicated in the inhibition of
nonspecific T cell contacts. In addition, under these steady state conditions, LC
do not exhibit competent B cell stimulatory capacity, as illustrated by the absence
of BAFF, a TNF family member, which is known to play an important role as a costimulator of B lymphocyte proliferation and function (8). Still, the authors admit
that although these LC isolated from steady state skin are quiescent and
sedentary, it is still possible that a fraction of LC mature and migrate to regional
LN under steady-state conditions.
LC continue to surprise researchers with regard to their key functions in
immune regulation. For example, it was recently found that LC were not
important in cutaneous antigen presentation in herpes virus infection, a lytic
process that involves apoptosis (5). Other studies of infectious immunology have
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revealed that LC don’t play a key role in immunity against Leishmania and
Candidal infections, and may even be immunoregulatory (59,60). For example, a
report using both models of LC ablation to study Candida infection has
demonstrated increased immune responses pointing to LC role in immune
suppression. More recently, Hogquist and colleagues showed that radioresistant
langerin+ DCs (presumably LC) are dispensable for peptide antigen presentation
in their K14-OVAp/K14-mOVA/Lang-DTR mouse model in which an MHC class Irestricted peptide is expressed under the K14 promoter (61).

LC ROLE

IN

CHS:

A PROTOTYPE ASSAY OF ANTIGEN PRESENTATION AND

T

CELL

INDUCTION

Although, much evidence points to LC ability to be potent APC in vitro,
several studies in mouse models of LC depletion allude to the fact that LC role
may be redundant and dispensable in antigen-presentation. LC role in the
prototypic T cell response to haptens painted onto the skin as measured by
murine contact hypersensitivity (CHS) reactions remains inconclusive. In this
assay, hapten-specific T cell responses are measured in mice sensitized by
cutaneous application of hapten on abdomen or back, which are then challenged
several days later by painting the same hapten onto the ear. Inflammation is
measured by ear thickness (62). Based on an earlier study, which found that the
density of epidermal LC played a key role in induction of either CHS or tolerance
after skin sensitization with DNFB (63), one would predict that CHS reactions
would be absent or greatly attenuated in the absence of LC (64,65). However,
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things in the world of LC ablation and CHS are not that simple.
Reports employing LC depleted mouse models are heterogeneous. The
French group, who sensitized Lang-DTR mice with DNFB and treated with DT 3
days prior and 1 day after sensitization, showed no effect on CHS (19). The
Dutch group sensitized their Lang-DTR mice with trinitrochlorobenzene (and in
later study with oxazolone, (12)) 3 days after DT injection and showed slightly
diminished but not absent CHS (41). Whereas, the American group who used
Lang-DTA (constitutively depleted mice), developed an increased CHS reaction
to DNFB and oxazolone as shown by Dan Kaplan group (43). Moreover, an even
more recent report by Kaplan and colleagues using a Lang-DTR mouse model
showed that acute inducible ablation of LC similarly results in increased CHS
reactions (44).
It appears that the timing of DT administration in Lang-DTR mice can affect
the outcome, since interestingly when the French mice were treated with DT only
on day -1, they developed diminished CHS responses similar to the Dutch mice
(16,66). The reason could be that the timed DT treatments make sure all dermal
langerin+ DC were gone. CHS responses were indeed decreased when all
langerin+ skin DC were absent (by sensitizing closer to DT injection), but restored
to wild type levels once the langerin+ dermal DC subset had returned
(sensitization 7 or 13 days after DT) (12). This suggested that langerin+ dDC
exerted an essential immunogenic function in CHS, but still contradicted the
reduced CHS observed by the Dutch group (41).
As hypothesized by Clausen and colleagues (42), the above discrepancy in
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the Dutch group may be explained by the amount of hapten used in sensitization.
It is possible that when limited amounts of antigen was applied (as by the Dutch
group) langerin+ DC were present, but antigen did not reach them, resulting in a
decreased CHS response. Thus, antigen dose, application site and thickness of
skin, which limits diffusion of antigen, may be important factors that will
determine the efficiency of epicutaneous immunization and which skin DC subset
will induce the immune response. This was recently supported by the Clausen
group, who verified this hypothesis by demonstrating attenuated CHS in the
absence of all langerin+ cells applying both a low and a higher dose of hapten
onto the skin. In contrast, in the selective absence of epidermal LC, CHS was
only diminished at a low hapten dose, but restored to wild type levels at a higher
concentration, that is when enough hapten penetrated through the epidermis and
across the basement membrane to reach the dDC (42).
In parallel to the above findings, in bone marrow chimera experiments
selectively depleting dermal langerin+ DC, Honda et al. found CHS responses
similar to wildtype when epidermal LC and langerin-negative dermal DC were
present (1,60). The type of hapten does not seem to matter, since when the
Clausen group compared the two Lang-DTR mice (19,41), using two different
haptens (Oxazolone and DNFB) and controlling for other variables, they saw no
differences in their CHS responses (42). In summary, it seems that antigen dose
and the number of skin DC that have access to the hapten, which subsequently
prime antigen-specific T cells in skin-draining lymph nodes, determine whether or
not reduced CHS develops as compared to wild type mice.
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Until recently, there were no other reports of the inducible Lang-DTR

models to have enhanced CHS as observed in Lang-DTA mice with constitutive
LC deficiency. Some hypothesized that in the acutely inducible depletion the still
reduced levels of dDC and/or CD8+ langerin+ DC prevented what otherwise
would have been an enhanced response in the absence of LC (39). Moreover,
given other reports of spontaneous autoimmunity in mice constitutively lacking
DC (67), others thought that it is possible that Lang-DTA mice have altered
responses to hapten sensitization or different T cell properties, involving LC
expression of MHC class II and IL-10 in controlling immune responses (60,68).
The latter speculation becomes obsolete since Kaplan and colleagues recently
demonstrated that acutely ablated LC (in a Lang-DTR model that does not affect
langerin+ dDC) had increased CHS responses similar to the group’s earlier
findings in their constitutively ablated LC model (44). Thus, this finding in a model
what has intact langerin+ dDC again reinforces the possibility that attenuated
levels of langerin+ dDC in other acutely ablating LC models may be responsible
for previous reports of decreased CHS responses. Some may question how LC
could induce a regulatory function in the inflammatory milieu of hapten
sensitization (69), but there are reports showing LC role in T cell regulation in
chronic inflammatory responses.

LC ROLE IN TUMORIGENESIS
LC role in cancer has long been studied and heterogeneous findings have
been reported regarding LC role in tumors of many organ systems. Initially, LC
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were thought to play an important role in tumor antigen presentation to induce
antitumor immune responses, but the LC paradigm has shifted to include LC as
possible immune regulators. Conflicting data exist on the number of LC in SCC,
BCC, cervical lesions and other cancers. No straightforward association with
tumors exist and both a decrease and increase in LC density have been
reported. For example, LC number may have been found to be decreased in
malignant lesions, showing as inverse relationship between LC and melanoma
thickness (70), or increased in lesions with better prognosis (71). However, this
seeming decrease in LC may have been related to the method of identification of
LC, back in the day using ATPase and S-100 or changing character of LC. For
example, Connor et al. has demonstrated decreased number of S-100 positive
LC associated with HPV peptide, but numbers of LC measured by CD1 were not
altered (72).
Maturity of LC in tumors have also been briefly addressed. Giannini et al.
report that LC are immature in squamous intraepithelial lesions (SILs) of the
cervix and are deficient in their presentation of alloantigens to T cells (73).
Golcalves et al. suggested that the increased presence of immature LC in
cervical intraepithelial neoplasia could be responsible for deficient presentation of
alloantigen to T cells (74). LC-depleted epidermal cells from melanoma patients
failed to augment lymphocyte responses to PHA and tetanus toxoid (75). Guess
et al. showed that HPV-16 E6 and E7 inhibit MIP-3α (Macrophage Inflammatory
Protein 3α/CCL20) transcription, resulting in suppression of the migration of
immature LC precursor-like cells (using CCR6), thus possibly inhibiting the
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immune alert systems and oncogene silencing induced LC migration (76,77).
Even in vivo mouse models fail to show a consistent role of LC in
tumorigenesis. Prior studies have shown that epicutaneous immunization of DC
with tumor material generates protective antitumor responses (78). A more
recent report by Stoitzner et al. followed up on that phenomenon in vivo and
demonstrated that LC played a critical role in the immunization process.
Depletion of LC by DT treatment (Lang-DTR mice) at the time of skin
immunization dramatically reduced the tumor-protective effect. The topicallyapplied antigen was presented by skin-derived LC in draining lymph nodes to
CD8 T cells. (79). Contrary to these findings, the Girardi group found that in
Lang-DTA mice (constitutively lacking LC), the absence of LC has a protective
effect on tumor development after two-stage chemical carcinogenesis. This
resistance to tumorigenesis of Langerhans cell–deficient mice was independent
of the presence or absence of either some or all γδ T cells (80).

CHEMICAL CARCINOGENESIS AND THE POTENTIAL TUMOR-PROMOTING ROLE OF LC
For many years, two-stage chemical carcinogenesis model has been used
to study stepwise and sequential analysis of tumor development, with the ability
to differentiate between tumor initiation and tumor promotion stages (81). The
initiation stage is accomplished by applying a single dose of a carcinogen like
DMBA, which is a polyaromatic hydrocarbon (PAH) used to model mutagens
present in the environment (pollutants, cigarette smoke, etc). It causes a
signature AT transversion mutation at position 2 of codon 61 of the Harvey-ras
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protooncogene that accelerates cellular proliferation and papilloma progression
(82,83). More than 94% of papillomas develop this specific mutation after the
two-stage chemical carcinogenesis protocol (84). The second, or tumor
promotion, stage of chemical carcinogenesis involves applying chemical agents
(i.e. TPA) or wounding that leads to sustained inflammation. TPA is a phorbol
ester that promotes low-grade inflammation observed in association with human
carcinomas. Basal keratinocytes are the key targets of carcinogenesis in this
model (85).
Chemical carcinogenesis has been classically associated with Ras protooncogene, and UVB carcinogenesis with p53 mutations, but the two processes
may be linked by sharing similar downstream regulators. For example, the
process of apoptosis (linked to reactive oxygen species, ROS) is shared in both
processes and can have a dual role in cancer processes (as discussed later).
One report found that, although oncogenic Ras has been demonstrated to
suppress p53 by enhancing its degradation via MDM2 in a Raf-dependent
manner (86), oncogenic Ras signaling has also been found to contribute to
apoptosis. A study by Zhao et al. (2006) has demonstrated that DMBA/TPA
application induces apoptosis in mouse skin epidermis and that the apoptotic
event was associated with increased p53 expression and mitochondrial
translocation (87,88). Later the same group demonstrated the role of Ras in this
p53-associated apoptotic event in a mutated Hras cell line after TPA treatment.
They found increased apoptosis (measured by cleaved caspase-3) and
increased upregulation of p53 (measured by a mitochondrial marker) was
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mediated by NOX (NADPH-oxidase) of neutrophils. In vivo analysis showed
similar finding only after DMBA+TPA, not DMBA-alone treatment. Furthermore,
another group, Ryu et al., who were investigating UVB-carcinogenesis found that
the NADPH oxidase family protein Nox1 lies downstream of BLT2 (a low-affinity
leukotriene B4 receptor) and mediates UVB-induced ROS production and
apoptosis (89).
Their strategic location in the epidermis and far reaching dendrites that
sample microparticulates from the environment allows for the potential role of LC
in tumorigenesis by interacting with self-antigens altered in chemical and UVB
processes. Preliminary data (Girardi et al., unpublished) and other reports (90)
suggest that LC may be involved in metabolism of mutagenic agents to higher
mutagenic material. Similarly, LC may be involved UVB carcinogenesis as they
are positioned suprabasally, where they may sense UV damage directly, or
indirectly through recognition of apoptotic vesicles and soluble mediators derived
from surrounding keratinocytes.

UVR AND UVR-DAMAGED KERATINOCYTES: MUTATED CLONES
In the UVR carcinogenesis model UVR appears to act as a tumor initiator
and as a tumor promoter (91), creating mutated cells and then promoting their
expansion by UVB-induced apoptosis (92). UV-radiation causes UVR-specific
mutations in keratinocyte DNA, most of which arise from errors in repairing
cyclobutane pyrimidine dimers (CPD) (93) that form at cytosine (C) molecules,
which are highly mutagenic because of error-prone repair that results in thymine
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(T) substitutions. These errors are responsible for much of the mutations within
the tumor suppressor gene p53 often found associated with human SCC (94)
and are prominently formed by DNA absorption of UVB, and to a lesser extent by
absorption of UVA. The cutaneous DNA damage action spectrum indicates that
the peak damage bandwidth occurs in the UVB spectrum at 300 nm (95).
However, UVA still remains a potential key player in skin cancer as it makes up
~95% terrestrial UVR, can penetrate skin more deeply and has less efficient DNA
repair mechanism (93). UVA-induced photodamage effects have principally been
attributed to the generation of reactive oxygen species (ROS) and the secondary
consequences of lipid peroxidation, protein oxidation and DNA oxidation,
particularly of guanosine nucleotides to form the ‘‘UVA signature’’ adduct, 8-oxo7,8-dihydro-2-deoxyguanosine (8-oxo-dG) (96,97).
UVR-induced tumors have been demonstrated by Kripke and colleagues to
be highly immunogenic and are rejected when transplanted into unirradiated
syngeneic mice (98-100). On the other hand, when the immune system of host is
downregulated by chronic UVB irradiation, it suppresses the rejection of these
tumors (99). Many biochemical and molecular factors have been identified as
important mediators of photodamage-related immune suppression (101,102),
such as trans-urocanic (UCA, present in stratum corneum), DNA, and sunburn
cells (apoptotic cells). For example, DNA-damage and UVR-transformed cis-UCA
have been shown to be involved in impaired APC function after UV irradiation
(103,104).
One way we can study progression of UVR carcinogenesis is by visualizing
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microscopic premalignant lesions of mutated p53 and aberrantly apoptosing
keratinocytes. Select mutant p53 keratinocytes progress to develop into clusters
of keratinocytes filled with p53 with altered conformations. These UVB-induced
microscopic lesions of mutated clones have been shown to be correlated with
subsequent number of tumors (105). Moreover, studies demonstrate that the p53
mutation profile of these UVB-induced skin patches are very similar to those
found in SCC, linking the mutated clonal patches as precursor lesions for SCC
(106).
Most precursor lesions regress (‘acute regression’) within 2-3 weeks (107).
Working on a Rag1 mouse model, Remenyik et al. found that acute regression of
UVB-induced p53 mutant clones is not mediated by antigen-specific immunity
(cells such as B, αβT, γδT cell); however natural killer (NK) T cells were still
present (108). It could be hypothesized that LC can influence mutated clone
progression or regression by directly (e.g. cell-cell interaction), or indirectly (e.g.
cytokine production) by regulating apoptosis.

APOPTOTIC SIGNALS IN KERATINOCYTES
Classically, apoptosis is viewed as a natural defense against cancer. One
of the earliest connections between apoptosis and cancer was the discovery of
the role of apoptosis regulator protein Bcl-2 in follicular lymphoma (109,110).
Moreover, ultraviolet-B (UVB) induced keratinocyte apoptosis has been viewed
as prevention of squamous cell carcinoma, by deleting UVB-induced DNAdamaged mutated cells proliferating out of control (94). P53 has a key role
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protective mechanism and consistent with its protective role, mutations in p53 are
a common finding in human SCC (111), and p53-knockout mice are highly
susceptible to both UVB (112) and chemical-induced SCC (113). However,
recently several groups have been reporting a paradoxical role for apoptosis in
processes involving carcinogenesis.
Genome instability caused by DNA damage requires checkpoints along the
cell’s life cycle, primarily regulated by the “guardian of the genome” tumor
suppressor gene p53, which serves a dual role of either arresting the cell cycle at
G1/S to allow repair, or inducing apoptosis. Keratinocytes respond to
extracellular and intracellular proapoptotic and antiapoptotic /survival signals.
Extracellularly, death receptors and their ligands activate the apoptotic pathway,
i.e. FasL/FasR, TNFα and TNF-R1 (114). Also, abrogation of cell-cell adherence
can elicit apoptosis (115,116). Moreover, intracellular signals (DNA damage,
oncogene action, survival factor insufficiency, ROS) can activate the proapoptotic
cascade (117). Intracellular signals, mediated by members of BCL-2 family
proteins can be proapoptotic (Bax, Bak, Bid, Bim, Puma) or antiapoptotic (Bcl-2,
Bcl-XL, BcL-W). Recent reports show that signals mediated by p53 and Bax, act
primarily via activation of p38 MAPK (118). Intercellular signaling eventually
converges on mitochondria activation and release of cytochrome C, whose
ultimate effectors are the intracellular proteases called caspases (119).
Similarly, the survival pathway has several ligand/receptor pairs that confer
survival of the cell, i.e. IGF1/IGF2 and IGF-1R, IL-3 and IL-3R (120,121). Other
prosurvival factors are FLIP, Bcl-xl and IAP molecules (i.e survivin) (122). Two
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cell survival pathways have been characterized. First, the MAPK pathway,
triggered by interaction of EGF/EGFR. EGF is known to protect against UVB
apoptosis and signaling via EGFR, and activates the MAPK cascade, promoting
MEKs and ERKs. The second survival path is also activated by EGR, which
involves phosphatidylinositol 3-kinase (PI3K), via activation of Akt. Akt in other
cell types inactivates Bad and caspase 9 (123), and in keratinocytes also
activates NFκB (124). Akt may promote survival in activating NFκB, by
upregulating survival factors such as IAPs (i.e. survivin). In addition to EGF, other
growth factors contribute to KC survival. For instance, reports show that
keratinocytes are protected against UVB-induced apoptosis by maintaining levels
of Bcl-2 and Bcl-XL (125), and activating Akt (126), through nerve growth factor
and hepatocyte growth (scatter) factor. Di-Poi et al., 2002 show that
transcriptional activation of nuclear peroxisome proliferator-activated receptors in
keratinocytes can also activate Akt (127).

SUNBURN CELLS
External perturbations, such as UV exposure, may activate both pro- and
antiapoptotic pathways, and the skin’s natural extracellular milieu stimuli
determine cell’s fate to either survive or apoptose (110). Interestingly, compared
to in vitro studies, keratinocytes in vivo are less susceptible to UV apoptosis. This
could be due to the survival factors present in skin in situ (and cell matrix
interactions mentioned above), such as laminin 5, which is an extracellular matrix
protein that binds to integrins and promotes cell survival via MEK/ERK signaling
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path activation (128).
Although a lot of useful data has been gathered using lines of cultured
keratinocytes, the study of apoptosis in sunburn cells in vivo after UVB exposure
is certainly more applicable to real life. Sunburn cells are UV-damaged cells with
hyperpyknotic nuclei and eosinophilic cytoplasm, which can be stained with
TUNNEL (129) or cleaved caspase-3 (130), and require activation of p53 (94),
which is thought to act via a transcriptional target galectin-7 (131). In addition to
upregulation of p53, reports saw upregulation of Bax and downregulation of Bcl-2
in UV-exposed skin (132). Sunburn cell formation seems to require activation of
Fas receptor (133-135), as well as UVB-induced DNA damage (cyclobutane
pyrimidine dimers, CPD) (136). Interestingly, in addition to activation of apoptotic
signals in response to DNA damage, there is also upregulaiton of E2F1 (shown
to be a survival factor in vivo), to balance the apoptosis (137).

PROTECTIVE ROLE OF APOPTOSIS IN CANCER
Several studies hint at the conflicting role of apoptosis in cancer (110,138).
They found that neither forced expression of apoptotic resistance nor deletion of
pro-apoptotic molecules in these studies is purely oncogenic. There is ample
evidence proving that apoptosis reduces mutations of damaged keratinocytes in
both chemical and UVR-induced processes. For example, UVB-induced
epidermal apoptosis minimizes accumulation of mutant epidermal keratinocytes
by several folds (133,139,140). Li et al. showed development of SCC after UVB
in p53 deficient mouse (112). Overexpression of MDM2 in the basal layer of
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epidermis

induced

hyperplasia

and

premalignant

lesions

in

chemical

carcinogenesis in K14-MDM2 mice (141). Bcl-x mice showed enhanced
chemically induced tumors, and increased malignant conversion (142). Suzuki
and others found that Pten activation accelerated tumor onset in chemical
tumorigenesis (143). El-Abaseri et al. showed that EGFR inhibitor treatment
reduced UVB tumorigenesis (144,145). In other studies, Stat3 deficient mice
were resistant to chemical treatment (146), and HK1.bcl-2 mice had increased
susceptibility to chemical treatment (147).

CONFLICTING ROLE OF APOPTOSIS IN CANCER
Greenhalgh (148) and Kemp (113) found that mice with reduced p53 (+/-)
resulted in increased resistance to tumor formation in chemical carcinogenesis,
but had an increased rate of malignant conversion. Similarly, Chaturvedi and
others reported that RNA interference-mediated reduction of p53 levels in
keratinocytes surprisingly enhances UVB-induced apoptosis (149). Dajee et al.
report that when they blocked NFκB (a survival factor that is activated in many
tumor types) keratinocyte transformation and SCC formation is enhanced (150).
Moreover, although Rel/nuclear factor κB transgenic mice have increased
keratinocyte apoptosis, they also spontaneously develop SCC (151). Mice
deficient in Cox-1 had increased keratinocyte apoptosis, but were associated
with reduction in UVB- induced tumors (130).
Data from other studies with models of decreased apoptosis or increased
survival resistance shows paradoxically decreased susceptibility to skin
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carcinogenesis. Such studies showed reduced numbers of papilloma formation
after chemical or UVB exposure, in models of K14-Bcl-2 (152) and K14-Survivin
(105,153). Moreover, some of these studies report the incidence of
hyperkeratosis in their mice ( (141,147), while others do not (Bcl-xL transgenic,
(142). Allen et al. surprisingly found that tumor formation was less frequent and
significantly delayed in K14-survivin mice compared with non-transgenic
littermates (153). Moreover, these anti-apoptotic transgenic mice had no
papilloma regression compared to controls and more conversion to SCC.
One way to reconsolidate the conflicting roles of apoptosis in tumorigenesis,
is to think of apoptosis as a necessary process for lateral expansion by a
mutated keratinocytes into nearing epidermal proliferating units (92). Zhang et al.
showed clones expand without new mutations (107) indicating that UVB is driving
clonal expansion by a physiological mechanism rather than by creating additional
mutations. As hypothesized by Brash et al., once a cell is mutated, it may
become resistant to apoptosis and may use UVB-induced apoptosis to break
boundaries of stem cell compartments (105), expanding without new mutations.
This group demonstrated that UV-induced apoptosis drives clonal expansion
during skin tumor development in their K14-survivin model (105).
This model predicts that in a mouse with reduced apoptotic capacity more
mutated cells will appear initially, but that these cells will expand into clones more
slowly than in wild-type animals. Survivin-regulated apoptosis appears to
suppress two stages that involve new mutations, initiation and malignant
conversion, yet drives clonal expansion of existing p53 mutant cells. In this way,
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tumor generation could actually be increased by apoptosis if greater clonal
expansion offsets the reduced mutation frequency (105). Although, survivin
expression was associated with decreased papilloma formation, there was an
enhanced rate of malignant conversion from papilloma to SCC in transgenic
animals. However, since it has been shown that transition from papilloma to SCC
(malignant conversion) involves new mutations, apoptosis would be expected to
exert a negative or protective influence at this stage as well.

LC AFTER UVB IRRADIATION
There have been discrepancies in reports describing what happens to LC
after UV exposure. Some reports demonstrate that LC migrate to draining LN
(103,154,155), while others show that they undergo apoptosis and still others
show that neither occurs.
Many of the earlier studies showing LC apoptosis after UVR were done in
vitro conditions. In vitro experiments demonstrated that LC went into apoptosis
after UVB irradiation and 2 days of culture (156). Another group found that death
of cultured murine LC is augmented by UVB irradiation (157). A population of
HLA-DR+ cells migrating from cultured, ex vivo irradiated skin explants are shown
to be apoptotic by binding of annexin V (158). One study showed by electron
microscopy that some human LC become necrotic when irradiated with UVB in
vitro (159). However, one has to interpret in vitro evidence with some caution, as
LC in vivo may be protected from apoptosis by shielding with several layers, but
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also by cell-cell contacts, cell surface molecules, and cytokines that are lacking
or different in vitro (160,161).
Kolgen et al. demonstrated in humans in vitro studies that only a few (<3%)
epidermal CD1a+ Langerhans cells in skin biopsies or blister roofs undergo
apoptosis after UVB exposure as detected by cleaved caspase-3 or TUNNEL
(162). They did not see evidence of LC necrosis and found cyclobutane
pyrimidine dimer (CPD) positive LC in blister fluid assumed to be en-route to
dLN. Okamoto et al. reported in mice that after UV radiation only 1.5 cell per 900
Langerhans cells per mm2 were apoptotic, believed to be too few to contribute to
the observed Langerhans cell depletion (163). McGee et al. show that neonatal
mouse epidermis does not have LC apoptosis or migration, instead
hypothesizing that LC depletion occurs from restriction of Langerhans cells
populating the epidermis (164).

LC ROLE IN UVR-INDUCED IMMUNE SUPPRESSION
UVR has long been known to cause immune suppression, either through
cytokines or induction of regulatory immune cells. For example, skin-infiltrating
monocytes/macrophages were shown to migrate to draining lymph nodes and
produce IL-10 after contact sensitizer exposure to UV-irradiated skin (165). UVRinduced T regs (regulatory T cells), which suppress hapten-mediated CHS, have
also been implicated in this process. UVR-T regs differ from natural T regs with
regard to their antigen specificity (166) and also from immunosuppressive drugs
that cause immunosuppression in a general manner (167). They express CD4
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and CD25 (168), the negative regulatory molecule CTLA-4 (169), glucocorticoidinduced tumor necrosis factor receptor (170), and bind the lectin dectin-2 (171).
In addition, they secrete IL-10 on hapten-specific stimulation (101,172) and may
use the apoptosis-related FasL/FasR-ligand system (62).
Earlier studies by Schwarz et al. demonstrated in Lang-DTR mice that
migration of UVR- damaged, but still viable, LC into lymph nodes appears to be
essential to induce regulatory T cells (T regs) (168). The UVR-induced T regs
appear to be critically dependent on the migration of LC into the lymph nodes
and the presence of UVR-induced DNA damage in the LC (155). This was
confirmed by the observation that IL-12, which reduces UVR-mediated DNA
damage (104,173,174), prevents the generation of UVR-T regs (175,176).
Langerin+ cells were still detected in the lymph nodes, but did not contain CPD.
These findings gave rise to the hypothesis that the appearance of UVR-damaged
but still viable LC in the regional lymph nodes is an essential event during the
generation of UVR-T regs. These authors also proved that prevention of UV
radiation-induced immunosuppression by IL-12 is dependent on DNA repair of
cis-UCA (155). Cis-UCA was found to inhibit the ability of Langerhans cells to
present tumor antigens for primary and secondary tumor immune responses, and
showed that IL-12 treatment completely prevented the suppression by cis-UCA
(104).
In a recent publication, the Schwarz group paralleled their earlier studies
above by demonstrating that Lang-DTR mice are resistant to UVR-induced
immunosuppression (177). However, in contrast to their findings and almost
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simultaneously, another paper published by the Hogquist group reported that LC
are not involved in UVR-induced immunosuppression (178). However, several
criticisms or limitations of the latter publications should be noted. For example,
role of T regs is unclear in the latter paper as only suppression of the induction of
CHS by UVR was studied and adoptive transfer experiments were not
performed. Another critique is that epicutaneous sensitization against ovalbumin
and transfer of OT-I cells were used as an immunological model. There is much
evidence that this system cannot be compared with the hapten-induced CHS
employed by Schwarz (179). Moreover, lower UVR doses and lower hapten
concentrations were applied, which might account for the differences in the
results. In addition, the authors claimed that UVR does not deplete LC, in
contrast to the literature (162). This alludes to the fact that UV doses used were
too low by Hogquist group, especially since the presence of LC was monitored in
epidermal cell suspensions, not in ear sheets.

LC ROLE IN IMMUNE SUPPRESSION
Extending the LC paradigm of LC maintaining peripheral tolerance via
engulfment of self-particles, one can hypothesize that an impaired cell immunity
or even induction of tolerance may contribute to inability to prevent tumor
formation. Can LC distinguish between transient formations of neo-self antigens
from stable expression of neo-antigens that mark an oncogenic event (93)? UVinduced immunosuppression is mediated via FasL/FasR system, an apoptosis
mediator (62,101,133). Similarly, Rossiter et al. made the observation that
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induced apoptosis resulted in paradoxical retardation of both UV and chemical
carcinogenesis (152) (see section Conflicting Role of Apoptosis in Cancer,
above). The direct interplay between LC and apoptotic keratinocytes is not well
characterized.

However,

given

above

conflicting

role

of

apoptosis

in

carcinogenesis, the controversial reports of LC inducing immune tolerance using
T regs and LC role in antigen-presentaion, we can try to reconcile these by
hypothesizing that apoptosis can induce immune tolerance and LC are somehow
involved. The type of antigen and the nature of the surrounding inflammatory
environmental milieu may affect the maturation and function of LC.
LC are strategically positioned just above the germinative layer in the
epidermis, where they can extend their dendrites and continually sample signals
of skin damage. After UVB exposure, LC have been reported to migrate, and
langerin+ CPD+ LC can be detected in draining LN 3 days after a 4-day UVB
exposure (103,180). LC may carry DNA-damaged, apoptosed cells and present
them to immune system (2,181). A report by Pradhan et al., in a mouse knockout
model of pro-apoptotic protein Bid (Bcl-2 family member), showed that the
absence of Bid-induced keratinocyte apoptosis abrogates UV-induced immune
tolerance (182). Moreover, several reports show evidence that the presence of
apoptotic cells during monocyte activation increases their secretion of the antiinflammatory and immunoregulatory cytokine interleukin 10 (IL-10) and
decreases secretion of the pro-inflammatory cytokines tumor necrosis factor
(TNFα), IL-1 and IL-12 (183,184).
Immature DC can induce T regs (185) and reprocessing of dying DC in LN

	
  

	
  

34	
  

by recipient DC could lead to tolerance (186). Skin-derived DC can mediate
deletional tolerance of class I-restricted self-reactive T cells (28). The role of LC
in immune regulation, such as graft rejection, is still controversial. One group
demonstrated that LC are not required for graft rejection (187), finding no
difference in the number of Foxp3 (T reg) cells. However they do admit that it’s
possible that LC may promote the development of T reg populations that do not
express Foxp3 or that there may be Foxp3 T regs induced in an antigen-specific
manner, but which are too few to affect the total number of Foxp3 cells (188). LC
may also primarily affect other cell types, such as plasmacytoid DC or NK
(natural killer) T cells, that have recently been reported to exert tolerogenic
effects in solid organ transplantation (189). Indeed, another DC subset,
plasmacytoid DC, has been recently shown to generate regulatory effects in
allografted mice treated with CD40L blockade (189). When bone marrow-derived
and epithelial DC are stimulated with factors like human thymic stromal
lymphopoietin, IL-10, and tissue growth factor-β, they have been shown to
promote tolerance to presented antigens (190,191). Keratinocytes are a major
source of both human thymic stromal lymphopoietin and tissue growth factor- β,
which raises the possibility that LC may be acting similarly (192).
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STATEMENT OF PURPOSE
Specific Aims:
1. To investigate the influence of Langerhans cells on the epidermal proliferative
response to DMBA (mutagen) and/or TPA (tumor promoter).
2. To investigate the influence Langerhans cells on the epidermal proliferative
response to acute and chronic ultraviolet B (UVB) light exposure.

Specific Hypotheses:
1A: There is decreased keratinocyte proliferation in LC-deficient mice in
response to DMBA+TPA, TPA alone and DMBA alone.
1B: There is decreased epidermal hypertrophy (minimal epidermal thickness) in
LC-deficient mice to DMBA+TPA, TPA alone and DMBA alone.
2A: There is increased epidermal apoptosis in LC-deficient mice in acute UVBexposure, as measured by cleaved caspase-3 and sunburn cells.
2B: There is a decreased number of mutated islands (mutant keratinocytes overexpressing p53) in LC-deficient mice after chronic UVB-exposure, as measured
by CM5 antibody by immunohistochemical and immunofluorescent staining.
2C: The area of mutant clones (clusters of mutant keratinocytes over-expressing
p53) is decreased in LC-deficient mice in chronic UVB-exposure as measured
by CM5 antibody by immunohistochemical and immunofluorescent staining.
2D: LC or other langerin+ DC will be present after acute and chronic UVB
exposure.
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AND

METHODS: All experiments were performed primarily by first

author, unless otherwise specified.

Mice
Transgenic mice that are constitutively depleted of LC (Lang-DTA) and those in
which LC ablation is inducible by DT (Lang-DTR) were generously donated by
Dan Kaplan (Minnesota, USA); the generation of these mice is described
elsewhere (Kaplan et al. 2009). A dose of 400ng of diphtheria toxin (DT) was
injected at 400nm/100uL intraperitoneally.

All littermates were genotyped for

transgene by PCR (by Renata Filler) and used at 7-9 weeks of age. Animal
procedures were approved by the Institutional Animal Care and Use Committees
at Yale University.

Chemical carcinogenesis
For all mouse skin, at seven weeks of age mouse dorsal hair was first clipped
(electric shaver), then treated with Nair (2-3 min), then washed off with water,
and covered with thin layer of petroleum jelly). A week later, a single dose of
DMBA (400nm/100uL, with 200uL tip) was applied and after 3 days we applied
TPA (twice-weekly Mon, Thurs, 20nm/100uL, with 200uL tip). Chemical
application was aimed at comparable location and area in all mice. During the
following weeks (4-5wks) dorsal skin of mice was shaved with clippers prior to
each repeated application of TPA. Treated (dorsal) skin was harvested one week
after the last TPA application, using a ruler to identify comparable areas and
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locations on the body. Skin strips were then either cryofrozen (using upside down
can of duster), or skin was formalin-fixed and paraffin embedded (latter part was
done by Yale Dermatopathology). For “DMBA only” studies, mice (DOB 5-10-09)
were treated with DMBA high dose (400 nmoles) on 07/06/09 and thereafter
once every 2 wks (total about 8 times).

Immunohistochemical Ki67 Staining of Paraffin Embedded or Frozen Sections
Cryosections were cut onto glass slides by author. Formalin fixed paraffin
embedded (FFPE) sections were cut by Dermatopathology. FFPE slides were
either baked for 20 min at 85°C or for 1 hr at 65°C, after which they were
deparaffinized by two washes of 5 min each in xylene, 100, 95, 70% ethanol and
water, citrate buffer in that order. Incubated slides in 3% hydrogen peroxide for
10min (use 500 mL 30%H2O2 in 4.5 mL dH2O, or 250 mL 30%H2O2 in 2.25mL
dH2O) and made new dilution every time. Heat induced antigen retrieval (HIAR)
was performed on FFPE (not cryosections) by steaming in preheated sodium
citrate buffer (pH6) for 10 min, cooling for 30 min and washing in dH2O three
times for 5 min. [Another method is boiling slides. Place slides in heated sodium
citrate buffer between 40 and 60°C. Once temperature reaches 95°C, heat for
20min between 95-98° C (letting reach 98 a couple times). Then cool to 35-40°C
on benchtop]. Wash for 3min in PBS two times. Apply primary antibody to cover
tissue, incubate for 30min at room temp on benchtop. [SP6 monoclonal Ki-67
antibody stopped working, so moved on to polyclonal, RB-1510-R7, Thermo
Fisher Scientific]. Wash for 5 min in PBS, x2. Applied secondary antibody in
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PBS, and incubated for 30min at room temp on benchtop. Mixed 5mL antibody
(biotinylated anti-rabbit IgG, made in goat by Neomarkers), 1 mL PBS, 25 mL
goat serum (as blocking agent by Vector labs). If using ABC reagent (instead of
Stretpavidin-HRP), be ready to prepare it 30 min ahead of applying it in the next
steps (1 drop A, 1 drop B, in 2.5mL PBS). Washed in PBS two times for 5min.
Applied ABC reagent and incubated for 30min at room temp. Washed two times
in PBS for 5min. Applied 200-300mL DAB until pigment fully developed, which is
anywhere between 1-8min (1 drop buffer, 2 drops DAB, 1 drop H2O2, all into
2.5mL HPLC water, mix well at each step). When pigment developed, quenched
by washing in distilled water, prepared in Coplin jar beforehand. Counterstain
with Haematoxylin and Bluing reagent. Wash gently three times with dH2O in
between and after. Place slides into Coplin jar with dH2O. Dehydrate slides
through xylene (30sec dH2O x2, 70% EtOH x2, 100%EtOH x2, xylene x2). Airdry in hood, coverslip with Permount (avoid bubbles), let dry flat overnight.

Immunofluorescence staining for p53/CM5, langerin/CD207, GL3 and cleaved
caspase-3
On staining day one (EDTA lysis, fixation, primary) harvested skin, scraped off
subcutaneous fat, and cut skin into strips. Incubated for lysis (2hrs) on dermal
side in EDTA buffer (pH 7.3) at 37°C in CO2 chamber. Separated epidermis and
dermis to obtain the epidermal sheets by scraping off the complete epidermis
with the forceps on a plastic plate, while holding and detaching the dermis with
forceps. Washed sheets 3 times in PBST (phosphate buffered saline with Tween)
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for 15min each. Next, fixed sheets by placing sheets as flat as possible on cover
slips and fix by immersing in cold acetone for 20min, on ice in the hood. Washed
two times in PBS for 10 min. Then, after positioning sheets basal side DOWN,
blocked (2% donkey or rabbit serum in 2% BSA) at room temperature on slides.
(Note: To position sheets, as you bring microscope stage toward lens, should
see stratum corneum first, then hair bulbs. Also, sheets tend to curl towards
basal side, but corneum side does tend to stick to itself). If many samples, keep
sheets on slides in 2% BSA to keep from sticking to slide, in covered chamber,
until last sheet positioned. Pipetted primary antibody on sheets.
Primary antibodies were rabbit CM5 (1:2000), rat langerin (1:200), hamster GL3
(1:100) and rabbit cleaved caspase-3 (1:200, Asp175, Cell Signaling Tech,
#9661) and mixed at appropriate concentrations cocktail (in 2% BSA) and
pipetted under sheets that are basal side DOWN on slides (used hydrophobic
pen for borders). Incubated overnight at 4°C.
On staining day two, sheets were washed in 15 mL conicals 2-3 times for 30min
in PBST (PBS with 0.05% Tween-20), on end-to-end rotator. Sheets were then
positioned basal side DOWN again (as described above) and pipetted in
secondary cocktail. Secondary antibodies were FITC-Donkey-anti-Rabbit (1:500,
JacksonImmunoResearch

#

711-016-152),

Cy5-Donkey-anti-Rat

(1:300,

JacksonImmunoResearch # 712-175-153), and goat Cy5-anti-hamster, 1:200)
and were mixed at appropriate concentrations under sheets positioned basal side
DOWN, and incubated for 1hr and 15min at room temperature. Washed with 2-3
washes of 30min, as before in PBST. Positioned sheets basal side DOWN again,
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as described above and pipetted in tertiary antibody (1:500, anti-FITC Alexa
488), which was incubated for 1hr at room temperature. Washed off tertiary
antibody, as before. Take out ProLongGold to thaw (at least 20 min), during the
washes. Mount and coverslip epidermal sheets basal side UP, (in ProLongGold)
on slides. (Note: Let edge of coverslip touch the mounting media, and let it fall;
don’t press too hard to get rid of bubbles.) Tacked with nail polish on all four
edges and leave at room temperature in dark slide holder for 24 hrs, before
viewing on confocal, to allowed to cure. Before handling slides, sealed all sides
with nail polish (to prevent coverslip movement) and kept at -20°C. Pictures were
obtained on Confocal (Zeiss, TAC LCM510 meta) or Dr. McNiff’s scope
(Dermatopathology, 5th floor) and statistics performed in Prism software.

Immunohistochemistry staining of cleaved caspase-3 of Formalin Fixed Paraffin
Embedded (FFPE) sections
On staining day one, incubated sections in 3% hydrogen peroxide for 15 minutes
and wash sections in dH2O twice for 5 minutes each. Washed section in wash
buffer for 5 minutes. Drew boundaries around samples on slides, with
hydrophobic pen. Blocked each section with blocking solution for 1 hr at room
temperature. Primary antibody rabbit cleaved caspase-3 (Asp175, Cell Signaling
Tech, #9661) diluted in recommended antibody diluent. Incubated overnight at
4°C, with covered plastic containers.
On staining day two, after removing antibody solution, washed in wash buffer
three times for 5 minutes each. Applied secondary antibody (biotinylated goat

	
  

	
  

41	
  

anti-rabbit, diluted in TBST) to each section. Incubated 30 minutes at room
temperature. [If using ABC avidin/biotin method, prepare ABC reagent according
to the manufacturer’s instructions and incubate solution for 30 minutes at room
temperature.] Remove secondary antibody solution and wash sections three
times with wash buffer for 5 minutes each. For the immunoperoxidase reaction,
added 100-400 µl ABC reagent (or Streptavidin-HRP) to each section and
incubate for 30 minutes at room temperature. Removed ABC reagent (or
Streptavidin-HRP) and washed sections three times in wash buffer for 5 minutes
each. For chromogen reaction, added 100-400 µl DAB to each section and
monitor staining closely. Quenched as soon as the sections develop, by
immersing slides in dH2O. Counterstained sections using Hematoxylin and bluing
reagent. Washed sections in dH2O two times for 5 minutes each. Then,
dehydrated sections by incubating sections in 70%, 95%, 100% ethanol and
xylene, two times for 30 seconds each. Mounted with toluene-based mounting
medium and coversliped (manually or using automated machine).

Quantification of stained cells by immunohistochemistry and
immunofluorescence
Counting of immunohistochemically stained cells was done by a blinded
observer, by identification of brown stained cells of Ki67 (RM-9106-R7,
ThermoFisher) or Cleaved caspase-3 (Asp175, Cell Signaling).

Positively

staining cells were quantified along a linear 250-µm grid at 400x high power field
on Olympus compound microscope (Dr. Bosenberg’s lab, 2nd floor). For
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immunofluorescent staining, mutant p53 clones were visualized as green clusters
(NCL-p53-CM5p; secondary FITC conjugated donkey anti-rabbit, followed by
Alexa488 conjugated anti-FITC). Most p53 mutations increase P53 protein
stability and allow antibody detection (ref 13,24). Langerhans cells (LC) or
langerin+ DC were visualized as blue cells (eBioRMUL.2; secondary Cy5
conjugated donkey anti-rat). Zeiss confocal microscope (TAC LSM510 meta)
was used to capture images, and ImageJ64 for analysis of islands.

UVB-irradiation in Acute and Chronic UVB Experiments
The UVB irradiation chamber was generously donated by Dr. Brash and
contained a bank of four UVB lamps (FS20T12- UVB; National Biological Corp.,
Twinsburg, OH) that emit wavelengths between 250 and 420 nm (72.6% UVB,
27.4% UVA, 0.01% UVC), with peak emission at 313 nm, according to the
manufacturer. A filter (Kodacel TA422; Eastman Kodak, Rochester, NY) was
placed over the cages to block residual UVC. There was a wire mesh to keep
mice from standing up. Dosimetry was determined using a calibrated UVB-500C
meter (National Biological Corp.). The irradiation rate was ~2.8 J/m2/s. Of note,
there is a possibility that UV dose was higher than measured at beginning of
experiments. After an acute exposure at the beginning of my time in the
laboratory the UVB dose measurement was 2.8 J/m2/s. However, upon repeating
the same experiment at the end of my time in the laboratory the dose was 4.2
J/m2/s. Reports of dose measurements checked by other members of the lab
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during the year was found to be higher. These inconsistencies may be due to
problems with UV box ventilation or leaving the bulbs on for a long time.
For acute UVB experiments, mice were clipped and naired as specified above
and one week later were exposed unrestrained to a single acute dose of
3,360J/m2 UVB applied to dorsal skin, which was harvested and paraffinembedded 24 hrs later. Similarly, for chronic UVB experiments, mice were
clipped and naired as above and chronic UVB (5wk, 9wk) was applied (Monday,
Wednesday and Friday) starting at 500 J/m2 then gradually increased to 1,250
J/m2 by week 3. This gradual increase in exposure produced minimal erythema
and was not associated with scaling or ulceration. Three days after the last
irradiation (to allow sufficient time for wild-type p53 up-regulated by UVB to return
to baseline levels, ref Zhang et al.), epidermal sheets were prepared from
multiple strips of dorsal skin as described above.
For acute UVB2 experiment actual mouse numbers were (3 Tg/Lang-DTA and 3
WT) were Tg# 19, 20, 21. For Acute UVB2 experiment the actual mouse
numbers and dates of birth (7 Tg/Lang-DTA & 7NLC) were Tg#165, 136
(DOB1/15), 143, 145, 148, 152 (DOB 1/12), 157 (DOB1/13), and NLC#137, 138
(DOB 1/15), 144, 146, 147, 153 (DOB 1/12), 158 (DOB 1/13).

9 weeks Chronic UVB1, Method 1: (Lang-DTA n=3, NLC n=3)
After 9 weeks of chronic UVB exposure mouse epidermal sheets were harvested
and stained as described above, and images were captured taken on Confocal
(Zeiss, TAC LSM510 meta) microscope only from middle strips from dorsal skin.
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Measured out, and marked 3 cm on each strip and moved along every 3000 µm,
for 10 high power fields (each HPF at 25x magnification is 0.1296mm2). Scanned
at 25x, then zoomed into each clonal island that touched the HPF. For clone size,
manually counted every bright cell per clone middle strip, for all samples except
3,26,32. Total area covered per mouse was 1.296 mm2 (0.1296mm2 times 10
HPFs). Actual mouse numbers were Lang-DTA # 5, 31, 14 and NLC #4, 27, 28.

9 weeks Chronic UVB1, Method 2: (Lang-DTA n=4, NLC n=4)
Pictures taken on Confocal (Zeiss TAC LSM510 meta) microscope only from
middle strips from dorsal skin. Collecting data from sheets involved scanning 3
big areas (1.8mm x 1.8mm, so 3.38 (actually 3.24) mm2 per area), by taking 25
HPFs (5 by 5 at 25x magnification). Area per 25x magnification is approximately
0.14 (actually 0.1296) mm2. Total area covered per mouse was 9.72mm2 (3 times
each area of 3.24mm2). Actual mouse numbers were Lang-DTA # 3, 5, 31, 14
and NLC # 32, 4, 27, 28.

5 weeks Chronic UVB2, Method 3: (Lang-DTA n=8, NLC n=7)
Pictures taken using fluorescent scope in Dermatopathology department (Dr. Jen
McNiff), to count the number of clones at 20x or per 0.9 mm2 (diameter =
1.07mm, radius = 0.535mm, thus Area= π*r2= 0.9mm2). Approximately 70 HPFs
were counted per mouse at 20x, which equals about 63 mm2 in area examined
per mouse. ImageJ64 was used to analyze clone size by outlining each clone
and measuring in µm2, which was then converted (multiplying by 106) to mm2 for
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data in graphs. Number of LC in Lang-DTA versus NLC mice after chronic UVB2
were analyzed for mouse numbers (n=4) for Lang-DTA (#5, 10, 12, 13) and for
NLC (#1, 2, 3, 6), by scanning three rows of 10 HPFs at 25x, for a total of 30
HPFs (each HPF area= 0.14mm2) on Zeiss confocal microscope. Also, quantified
the number of GL3 positive DC per HPF for Lang-DTA mice (#’s 5, 10, 12, 13
and 15). The actual mouse number and dates of birth were Lang-DTA#406, 407
(DOB 1/14), 417, 418, 442, 443, 444, 445 (DOB 1/17) & NLC#199, 200, 404, 405
(DOB 1/14), 409, 410 (DOB 1/14), 416 (DOB 1/17).

LC Associated with Mutated Clones in Lang-DTA and NLC mouse skin after 5
weeks of Chronic UVB2.
Data was gathered from mice from 5 weeks of chronic UVB2. Each HPF had two
3-dimentional layers from top of epidermis to bottom, at set distance. The
number of langerin+ DC were counted using ImageJ64 software. Badri Modi
assisted in counting using ImageJ64 and analyzing data in excel file. Designated
mouse numbers were Lang-DTA # 5, 9, 10, 12, 13, 14, 15 and for NLC # 1, 3, 6,
7, 8, 11. Using Zeiss microscope (TAC LSM510 meta), at 25x (HPF area =0.14
(actually 0.1296) mm2) scanned middle edge of skin strip for clones and areas
without clones for 10 HPFs. Tried to get a range for clone sizes (20-300 µm in
diameter). Initially, scanned 10 HPFs with clones, and another set of data with 10
HPFs scanned without clones (data not shown). However, since it was difficult to
find areas without clones near edge (closer to middle of mouse back) there may
have been bias with selecting HPF without clones closer to lateral side of mouse
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(where more LC may be present sue to less UVB exposure). To avoid the bias,
we used the HPFs only with clones (~10 HPFs per mouse) and compared the
number of langerin+ DC within or near (3 cells) to clone versus number of
langerin+ DC outside the clones in that HPF. For NLC however, scanned images
only with mutant clones (30 HPFs total per mouse).

5 weeks Chronic UVB3 and 3 Weeks Regression Method 4: (Lang-DTR n=7,
NLC n=7).
Mice were chronically irradiated for 5 weeks, followed by 3 weeks for regression
(no UVB exposure) and with DT injection at weeks 6, 7 and 8. Two strips of
dorsal skin (right and left) were harvested per mouse. Images of mutant clones
per HPF at 20x magnification (each HPF area= 0.9mm2) were taken using
fluorescent scope in Dermatopathology department (Dr. Jen McNiff). ImageJ64
was used to measure areas per clones in µm2, which was then converted
(multiplying by 106) to mm2 for data in graphs. Covered approximately 1245
HPFs at 20x for Lang-DTR and NLC, respectively, and thus about 11.2 cm2 in
total per group. Clones that were more than 3 cells apart and with different
morphology were counted as separate clones.

Cell counting for IHC stained sections (Ki-67, Cleaved caspase-3) and H&E:
All counting was done on Olympus compound microscope at 400x magnification.
Each high power field (HPF) was 250 um and was chosen randomly by a blind
observer. For Ki-67 (n=2), each slide contained a roll of skin in which the number
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of positive cells in the epidermis were counted by sampling 12 HPFs per mouse
along the 250 µm ruler. For the pilot experiment for acute UVB cleaved caspase3 staining and sunburn cell counting was done on the middle strips of dorsal skin
was used and 10-30 HPFs were randomly counted. For the repeated acute UVB
experiment, cleaved caspase-3+ cells were counted from slides with two strips
per mouse collected from the middle of dosal skin exposed to acute UVB dose
(3,360J/m2), along a 250-µm ruler, by randomly sampling 25 HPFs in each strip,
from middle of each strip, for a total of 50 HPFs per mouse. Sunburn cells were
identified as cells with: (i) pyknotic nuclei and/or (ii) eosinophilic cytoplasm, or
cells without nucleus with eosinophilic cytoplasm.

Statistics
For all cell and clone analysis, data derived from multiple animals was subjected
to unpaired, two-tailed Student’s t-tests using Prism GraphPad software (Mac
OSX version). Analysis of p53 mutant clones was performed using ImageJ64
(National Institute of Health, USA). For analyses of differences in clone density
within predetermined size ranges (bins), the assumption was made that the
random observed number of clones of a given size should follow a Poisson
distribution, with mean proportional to the total area. P values of ≤0.05 were
considered statistically significant. Mean values with ± SEM were reported.

	
  

	
  

48	
  

RESULTS
CHEMICAL CARCINOGENESIS EXPERIMENTS:
DMBA + TPA, TPA ALONE AND DMBA ALONE
DMBA + TPA: After two-stage chemical carcinogenesis (DMBA +TPA), there
was significantly smaller increase in epidermal proliferation and epidermal
thickness in Lang-DTA mice vs NLC mice.
At baseline, LC-intact (NLC) and LC-deficient (Lang-DTA) mouse skin
showed comparable proliferation levels (Figure 1a) as measured by Ki-67
immunohistochemistry, IHC (13.6 ± 2.6 vs 12.7 ± 2.8 #Ki-67+ cells, P=NS) and
comparable minimal epidermal thickness (7.9±1.8 vs 6.9±2.8 µm, P=NS, Figure
1b). After a single application of mutagen DMBA, followed by repeated
applications of tumor promoter TPA (x 5.5 wks), LC-depleted skin showed 23%
smaller increase in epidermal proliferation (31.5 ± 7.7 vs 25.7 ± 7.4 # Ki-67+
cells, P=0.007) and minimal epidermal thickness (59.2 ± 28.4 vs 25.8 ± 8.9 µm,
P<0.0001), as compared to LC-deficient skin. Minimal epidermal thickness was
measured from basal to granular layer of the epidermis.

TPA alone: After 4 weeks of TPA application, there was significantly
smaller increase in epidermal proliferation and epidermal thickness in
Lang-DTA mice vs NLC mice.
After repeated applications of tumor promoter TPA (x 4 wks), LC-depleted
(Lang-DTA) skin showed a smaller increase in epidermal proliferation (16.7 ± 0.4
vs 19.3 ±0.5 # Ki-67+cells, P=0.0002, Figure 3a) and minimal epidermal
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thickness (5.1 ± 0.1 vs 8.5 ± 0.2 µm, P<0.0001, Figure 3c), as compared to NLC
mice. Statistical significance was not reached for means per mouse for epidermal
proliferation (P= NS, 0.3982, Figure 3b), but was reached for epidermal
hypertrophy as (P=0.0037, Figure 3d).

DMBA alone: After 8 times of mutagen (DMBA alone) treatment every 2
weeks, there was a significantly smaller increase in epidermal proliferation
and epidermal thickness in Lang-DTA mice vs NLC mice.
After repeated applications of mutagen DMBA alone, Lang-DTA skin
showed a smaller increase in epidermal proliferation (12.8 ± 0.99 vs 22.7 ± 1.4 #
Ki-67+cells, P=0.0001, Figure 4a) and minimal epidermal thickness (14.4 ± 1.08
vs 17.8 ± 1.0 µm, P<0.0292, Figure 4c), as compared to NLC skin. FIgure 4b and
4d show corresponding data per mouse.
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RESULTS FOR ACUTE UVB EXPERIMENTS

Acute UVB (formalin-fixed epidermal sections): After a single dose of UVB
(3,360 J/m2), there was a significantly smaller number of apoptotic cells
(cleaved caspase-3 and sunburn cells) in the epidermis of Lang-DTA
versus NLC mice.
A pilot experiment (n=3) showed LC-deficient skin (Lang-DTA), as
compared to skin of LC-intact normal littermate controls (NLC), to have less
epidermal apoptosis after acute UVB irradiation, as measured by IHC on
formalin-fixed sections (21.4 ± 1.1 vs 26.4 ± 1.4 # cleaved caspase-3+ cells,
P=0.0099, Figure 5) and on H&E (9.3 ± 0.5 vs 13.9 ± 1.5 # sunburn cells, P=
0.0069, Figure 6a). Statistical significance was not reached for the means per
mouse, for either cleaved caspase-3 or sunburn cells (22.57 ± 3.548 vs 28.26 ±
5.441 # cleaved caspase-3+ cells, P=NS, 0.4303, Figure 5b) or sunburn cells
(9.2 ± 1.5 vs 14.4 ± 3.8, # sunburn cells, P= NS, 0.2678, Figure 6b), as well as in
the combined means per mouse data (n=10) for both pilot and repeated
experiment (19.77 ± 1.7 vs 22.7 ± 2.1 # cleaved caspase-3+ cells, P= NS,
0.2877, Figure 8b).
Figure 8a contains combined apoptosis data from pilot acute UVB
experiment (n=3) and repeated (n=7) experiment measuring cleaved caspase-3
for Lang-DTA vs NLC irradiated skin on formalin-fixed sections. There was a
statistically significant difference in epidermal apoptosis (18.9 ± 0.4 vs 21.1 ± 0.4
# cleaved caspase-3+ cells, P< 0.0001). At baseline (Figure 8a), non-irradiated
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anterior belly skin showed no difference in apoptosis in Lang-DTA vs NLC skin
(0.01 ± 0.0 vs 0.01 ± 0.0 # cleaved caspase-3+ cells, P= NS, 0.3692).
Figure 7a shows cleaved caspase-3 data for the first (pilot) experiment
(n=3) per each strip 1-3, where strip 2 corresponds to the middle dorsal treated
skin, and strips 1 and 3 are side strips. Of note, previously shown data in Figures
5 and 6 are from middle strips (i.e. strip 2 from each mouse). Figure 7b contains
all the cleaved caspase-3 data per mouse for both old and repeated experiments.

Acute UVB (epidermal sheets): After a single dose of UVB (3,360 J/m2),
epidermal sheets were co-stained with cleaved caspase-3 and langerin
(CD207) by immunofluorescence in Lang-DTR and NLC mice.
Experiment ‘Acute UVB Sheets1’ found that NLC mouse epidermal sheets
show several cells double-stained with cleaved caspase-3 (green) and
langerin/CD207 (blue) at 25x magnification in Figure 9 for NLC and in Figure 11
for Lang-DTA, and at 63x magnification in Figure 10 for NLC and in Figure 12 for
Lang-DTA mice.
A follow-up experiment ‘Acute UVB Sheets2’ similarly revealed some costaining of langerin and cleaved caspase-3 positive cells. Plus, anterior belly skin
(unexposed to UVB) was also found to be stained for the apoptotic marker in
both Lang-DTA and NLC mice (Figures 13 a and 13b). In this follow up
experiment ‘Acute UVB Sheets2’ there was a lot of heterogeneity in number of
langerin+ cells in both Lang-DTA and NLC. For example, sometimes there was
an unusually high number of langerin+ cells in Lang-DTR group, as in Figure 13b
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(panels 4-6), which may be due to inadequate depletion by DT. On the other
hand, sometime there was an unusually low number of langerin+ cells in NLC as
in Figure 13a (panels 4-6), which could be due to random location on skin. A
relatively small area of skin was examined and a repeat experiment needs to be
conducted. IgG control for cleaved caspase-3 was not completely clean (see
Figure 14c, panel 1). IgG control for langerin/CD207 was clean (see Figure 14c,
panel 2).
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RESULTS FOR CHRONIC UVB EXPERIMENTS

3 Weeks (Chronic UVB0) and 9 weeks (Chronic UVB1): Mutant Clones and
LC in Skin of Wildtype Mice.
After chronic UVB exposure, NLC mouse skin contains p53-mutant clones
and viable (with long dendrites) langerin+ DC by immunohistochemistry
(langerin/CD207).

These

cells

also

stain

for

MHC-class

II

by

immunofluorescence (data not shown). Figure 15a shows p-53 mutant clones
(CM5, IHC epidermal sheets, brown) after 3 weeks of chronic UVB. Figure 15b
shows a larger p53-mutant clone after 5 weeks (courtesy of Wengeng Zhang).
Figure 15c shows langerin+ DC (CD 207, IHC epidermal sheet, brown) after 3
weeks of chronic UVB. Our data show that clones increase in number and size
with increased time of UVB exposure (see Figure 21). We have also observed
variation in morphology of mutant clonal cells (see Figure 28).
Immunofluorescence staining after 9 weeks of chronic UVB revealed large
mutant clones surrounded by and permeated by langerin+ DC, as seen in Figure
16a. Velocity software analysis of captured stacks of two-dimensional slices from
epidermis to dermis, allows viewing these cells in three-dimensions (see Figure
16b).
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After chronic UVB exposure (3x/wk, increasing dose from 750 to 1250J/m2
for 9 and 5 weeks) dorsal skin of Lang-DTA mice revealed a smaller number
of clones of mutated p53 keratinocytes compared to NLC mouse skin.

9 weeks (Chronic UVB1): Number of Clones in Lang-DTA vs NLC

Method 1 of collecting data involved taking 10 HPF's at 25x for each
mouse (n=3 per group), covering approximately 1.296 mm2 per mouse. After 9
weeks of chronic UVB exposure, Lang-DTA mouse skin compared to NLC had a
smaller number of mutated clones per mm2 (8.0 ± 1.1 vs 15.4 ± 2.3, P=0.004,
Figure 17a). Statistical significance was not reached for means per mouse (10.7
± 2.2 vs 16.9 ± 4.2, P= NS, 0.2636, Figure 17c). Figure 17b shows data per HPF
per mouse.
Method 2 of collecting data involved taking 3 larger areas (3.24 mm2 each)
for each mouse (n=4 per group), covering 9.72 mm2 per mouse. After 9 weeks of
chronic UVB exposure, there was a trend toward Lang-DTA mouse skin having a
smaller number of mutated clones per mm2 compared to NLC (1.7 ± 0.3 vs 2.5 ±
0.5 # mutated clones/mm2, P= NS, 0.1636, Figure 18a), which did not reach
statistical significance. Means per mouse also did not reach statistical
significance (1.7 ± 0.3 vs 2.4 ± 0.7 mean # mutated islands/mm2, P= NS, 0.3528,
Figure 18b).
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There is a discrepancy in the number of clones per mm2 in Method 1

versus Method 2 at 9 weeks of chronic UVB, with the former being approximately
5-6 times greater (represented visually in Figure 21a and 21b). There are two
possible explanations for this. One: in Method 1, each clone that touched the
edge of the HPF at 25x was zoomed into and also counted, even if it was outside
the HPF, but the area was not accounted for. Second: the Method 2 of counting
clones may have missed some, since the bigger area (3.24 mm2 vs 0.1296 mm2)
was captured in lesser resolution.

5 weeks (Chronic UVB2): Number of Clones in Lang-DTA vs NLC
Method 3: After 5 weeks of chronic UVB exposure, Lang-DTA mouse skin
had a smaller number of mutated clones per mm2 compared to NLC (0.9 ± 0.05
vs 1.0 ± 0.1 # mutant clones/mm2, P=0.0489, Figure 19a). Statistical significance
was not reached for means per mouse (0.9 ± 0.1 vs 1.1 ± 0.2, P=0.3797, Figure
19b).

5 weeks UVB and 3 weeks regression (Chronic UVB3): Number of Clones in
Lang-DTR vs NLC
Method 4: After 5 weeks of chronic UVB followed by 3 weeks of no UVB
(and DT injection at weeks 6, 7 and 8), there was a smaller number of mutant
clones per mm2 in Lang-DTA mouse skin versus NLC (0.2 ± 0.0 vs 0.4 ± 0.0, P<
0.0001, Figure 20a). Statistical significance was also reached for mean number
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of mutated clones/mm2 in Lang-DTA vs NLC per mouse (0.2 ± 0.0 vs 0.4 ± 0.0,
P=0.0106, Figure 20b).

Area of Mutant Clones
Mutant clone size was not statistically different in LC-deficient versus NLC
group. However, there seemed to be an overall skew toward smaller area in
Lang-DTA mice versus NLC after 9 weeks (34.2 ± 7.4 vs 46.3 ± 9.2 #cells/clone,
P= NS, 0.3375, Figure 22a) and 5 weeks of UVB (0.041± 0.00 vs 0.047 ± 0.01
mm2, P=NS, 0.2695, Figure 22b). Interestingly, the general trend almost reversed
after mice had 3 weeks time to regress their clones following the 5 weeks of UVB
(0.034 ± 0.00 vs 0.031 ± 0.00, P= NS, 0.5590, Figure 22c ) and Lang-DTA mice
seemed to have more larger clone sizes (not statistically significant).
Arranging clone areas into bins, as done by Zhang et al 2005 (ref) in
Figure 24, whose authors organized area bins by 1-16, 17-32, 33-48, 49 -160,
161-499, with 16 being the number of cells for the fundamental unit of EPU
(epidermal proliferating unit). Zhang et al. found that their transgenic mouse
model (K14-survivin mice) that was resistant to apoptosis had more clones in the
smaller areas ranges (1-16 cells). A similar trend is seen in our Lang-DTA mice
(preliminary data showing decreased apoptosis). Possibly, this is due to DNAdamaged cells not being ablated by decreased apoptosis early in the UVB
process, leaving behind many more mutant clones as compared to NLC mice.
Thus, in all three of our experiments (9 weeks, 5 weeks, and 5 weeks+ 3
weeks no UVB) there seems to be a slight trend toward a greater number of
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smaller clones (<16 cells) in Lang-DTA and Lang-DTR mice. The 9 week
experiment is most consistent with Zhang et al. results, perhaps because clone
areas were counted manually and also mice were irradiated for longest time.
In experiments that we used to measure area by outlining the clones, the
bin with 33-48 cells per clons has a trend toward Lang-DTA mice having greater
area per clone versus NLC, as seen in Method 3 at 5 weeks (0.038 ± 0.01 vs
0.011 ± 0.01, P=0.0601, Figure 23b) and in Method 4 at 5 weeks UVB and 3
week regression (0.0989 ± 0.02 vs 0.0736 ± 0.01, P= NS, 0.3038, Figure 23c).
Zhang et al. manually counted the cells in each clone, stained by
immunohistochemistry. For Method 1, we also counted cells manually. However,
for further experiments, it was not feasible for us to count each cell in clones in
real-time using a confocal microscope, so instead we captured images by a
confocal microscope and measured the area by outlining the clones using
ImageJ64 software. Then, the area was converted to cells per clone by dividing
by 80 µm2, which was the average area per cell accounting for intercellular
surrounding space. The fact that we don’t see the same distribution as in Zhang
et al. may be due to the fact that the area to cell conversion is not perfect, as
each cell varies in size and morphology, as well as spatial arrangement within
the clone (see section on Mutant Clone Morphology, below).
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LC Number in Lang-DTA vs NLC after 5 weeks of chronic UVB of dorsal
skin:
After 5 weeks of chronic UVB, Lang-DTA mice have approximately 12
times less ‘replacement’ langerin+ DC compared to NLC mouse skin (23 ± 0.46
vs 278 ± 17 # langerin+ cells/mm2, P< 0.0001, Figure 26a).

LC Density Associated with Mutant Clones in Lang-DTA and NLC after 5
weeks of chronic UVB of dorsal skin:
After 5 weeks of chronic UVB, ‘replacement’ LC (see Figure 25) are
associated with mutant clones in Lang-DTA mice as compared to areas without
clones (61.0 ± 9.1 vs 19.7 ± 2.7 # langerin+ cells/mm2, P< 0.0001, Figure 27a).
Statistical significance was also reached for mean density per mouse (P=0.0106,
Figure 27b).
A similar association was seen in NLC mice. After 5 weeks of chronic
UVB, LC were associated with mutant clones in NLC mouse skin as compared to
areas without clones (242.4 ± 21.4 vs 163.8 ± 15.3 LC density (mm2), P= 0.0047,
Figure 27c). Mean density per mouse missed statistical significance (P= 0.1848,
Figure 27d).

Mutant Clone Morphology: Epidermal proliferating units (EPUs) expand
into clonal islands. Mutant clones are made up of p53-mutant keratinocytes
that fill up the epidermal proliferating units (EPUs) as ~16 cell units, which are
hexagonal in shape (Figure 28 a-c). These mutant EPUs coalesce into larger
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units, around the hair follicles (Figure 28 d-e). Moreover, these clones are made
of keratinocyte cells of different sizes, from small (as seen in clone on bottom half
of Figure 28e) to larger sizes (clone on top of Figure 28e). Sometimes, the cells
became disproportionately big as compared to surrounding cells in the clone
(Figure 28d).

DETC and LC in Lang-DTA Mice: There is a drastic decrease in GL3positive DETCs after 5 week chronic UVB exposure and some were seen
interacting with langerin+ DC. Figure 29 a-b is from the skin of a Lang-DTA
mouse, which shows DETC (GL3+, red) interacting with langerin+ DC (CD207,
blue), next to mutant clone (CM5, green). Figure 29b is a close up of this DETC
and LC interaction. Figure 29c shows that there is no significant relationship
between GL3+ cell density and presence of clones in HPFs in Lang-DTA mice
(3.2 ± 0.7 vs 4.2 ± 1.4 #GL3+ cells/mm2, P=(NS) 0.4966). Baseline numbers of
GL3+ cells from non-irradiated anterior bellies have not yet been quantified.
However, if there is an average of 0.47 GL3+ cells per HPF at 25x, then there
seems to be an approximate 80-fold decrease in GL3+ cells as compared to
anterior belly control (approximately 40 GL3+ cells/HPF non-irradiated, Figure
29f) in Lang-DTA mouse skin. Many GL3+ cells were located within or near hair
follicles, as show in Figures 29 e-f.
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DETC and LC in NLC Mice: There is a drastic decrease in GL3-positive
DETCs after 5 week chronic UVB exposure and some seen interacting with
langerin+ DC. Figures 30 a-d show DETC (GL3, red) interacting with langerin+
DC (CD207, blue) in NLC mouse skin. Figures 30b and 30c different planes of
same image. Figure 30c has a scattered clone (CM5, green) in the background.
Figure 30e is anterior belly control for NLC (non-irradiated). Many GL3+ cells
were located in or near hair follicles.
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DISCUSSION
As seen from our preliminary data, there are several postulations that can
be made regarding what processes LC may be affecting in the epidermis to
cause increased tumorigenesis in chemical models and increased premalignant
lesions in UVR models. Previous findings from the Girardi lab revealed that LC
have a fundamental role in tumorigenesis, as LC-deficient (Lang-DTA) mice were
shown to be significantly resistant to two-stage chemical carcinogenesis.
Moreover, our more recent preliminary findings suggest that LC facilitate
keratinocyte proliferation and epidermal hypertrophy (Figure 1 a-b). We
hypothesized that LC may be affecting the initiation step of carcinogenesis,
where a mutagen (i.e. DMBA) causes DNA-damage that results in mutations that
cause aberrant cell proliferation. To this effect, our laboratory revealed
preliminary evidence that LC may have the capacity to internalize mutagens (i.e.
DMBA) and metabolize them to more carcinogenic intermediates (unpublished).
On the other hand, LC may also be acting at the tumor promotion stage,
where post-mutational events may contribute to neoplasia, controlling cell cycle
dysregulation and apoptosis. For example, the fact that much of LC effect on
epidermal proliferation and hypertrophy can be observed with TPA alone (Figure
3) indicates that this effect is not entirely dependent on mutagenesis by DMBA.
Thus, since LC absence has a negative effect on proliferation and hypertrophy in
DMBA+TPA (Figure 1), TPA alone (Figure 3), and even DMBA alone (Figure 4),
it suggests LC may have a role in both initiation and promotion in carcinogenesis.
Since the initial DMBA+TPA experiment was only a small sample (n=2), a repeat
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chemical carcinogenesis experiment (DMBA and 4 weeks of TPA) has been
completed to confirm the findings and is awaiting analysis.
Because we saw such a drastic effect of the presence or absence of LC
on keratinocyte proliferation in chemical carcinogenesis, we were interested to
study the influence of LC on UVB carcinogenesis under both acute and chronic
exposure conditions. It was surprising to find that the presence of LC is
correlated with increased epidermal apoptosis (Figure 8), since apoptosis has
been classically associated with protective effect in cancer and we have
hypothesized that LC somehow promote cancer in the skin of mice. However, as
already discussed in the introduction, apoptosis has been more recently
described to play an important role in the expansion of a mutated clone into
nearing stem cell compartments in the epidermis (105).
After repeating the acute UVB experiment with a greater number of mice,
the same trend was observed. There is a question whether the increased levels
of apoptosis was secondary to LC themselves apoptosing, thus raising our cell
counts in the NLC mouse group. It is not completely clear from the literature what
happens to epidermal LC during UVB exposure. Earlier in vitro reports claimed
that LC apoptosed after UVB exposure (156-158), however later in vivo studies
demonstrated that only a few LC undergo apoptosis and depletion was mainly
attributable to migration (162,163). One report examined LC apoptosis more than
48 hours after UV at increasing doses and found LC have delayed apoptosis
(182).
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In a pilot experiment, we co-stained epidermal sheets of Lang-DTR and

NLC mice (Figure 9) with cleaved caspse-3 (apoptosis marker) and
langerin/CD207 (LC marker) by immunofluorescence. While we did not have
enough mice to make a detailed comparison, we could see that not all LC were
co-stained with cleaved caspase-3. However, just by looking at co-staining we
could not distinguish between LC that may be apoptosing and those that may be
engulfing apoptotic keratinocytes. One way to distinguish apoptosing LC from
ones that are engulfing apoptosing keratinocytes would be by LC morphology. As
described by Pradhan et al. (182), the morphology of wildtype LC differed
strikingly from apoptosis resistant KO LC on day 7, most occurring by day 2.
They report that LC developed enlarged rounded cell bodies with ‘blebbing’ (at
1000 J/mm2), as well as diffuse smeary (500 J/mm2) or ‘blebby’ dendritic
processes (2000 J/mm2), providing morphological hallmarks of apoptosis in situ
(182). In our preliminary data LC staining did show some blebbing, but that may
be due to staining methods. Ideally, this experiment should be repeated with an
unirradiated dorsal skin control and the morphology of the LC noted. Our
preliminary data suggests that LC can facilitate keratinocyte apoptosis after acute
UVB, but more research needs to be done to confirm this finding.
Another reason why we may not be seeing a strong difference in
apoptosis marker in LC-deficient versus NLC mice may be due to a possibility
that our UV-box produced a supra-physiological dose of UVB. A very high
amount of keratinocytes were apoptosing after our calculated dose of 3,360 J/m2
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and it’s possible that may have just flooded the system to see any strong
differences.
Nevertheless, if we hypothesize that LC presence indeed influences the
level of keratinocyte apoptosis in the epidermis and that apoptosis promotes
mutant clone expansion, this would be consistent with our findings in chronic
UVB experiments, where LC-deficient mice (Lang-DTA and Lang-DTR) were
found to have a statistically significant smaller density of p53 mutant clones.
Mutant clones have been described to consist of p53-mutant keratinocytes that
fill up the epidermal proliferating units (EPUs) as 16-cell units, which are confined
or “trapped” by hexagonal geometry of an EPU without further UVB irradiation
(107). Clonal expansion has been shown to be driven not by new mutations, but
by UVB-induced keratinocyte apoptosis (105). Brash group describes this
conflicting role of apoptosis in their K-14 survivin transgenic mice, which are
relatively resistant to apoptosis compared to wildtype mice. Their transgenic mice
had a decreased number of microscopic clones and corresponding decreased
numbers of papillomas, but interestingly had increased malignant conversion
(tumor transformation) to squamous cell carcinoma.
Thus, if we compared our LC deficient mice to K-14 survivin mice (both
have less apoptosis relative to controls), it is not surprising that both transgenic
mice have deceased numbers of mutant clones compared to control mice.
Moreover, clonal numbers binned by clone sizes followed a similar pattern
described in the Brash group’s K14-survivin transgenic mice (Figure 21),
especially for our 9 week mice. We saw a similar trend (although not statistically
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significant, i.e., p=0.06 in a two-tailed t-test for bin 33-48 cells) of increased
numbers of smaller clones in the mouse group with relatively less apoptosis (K14 survivin mice and our Lang-DTA/DTR-mice).
Moreover, in the regression experiment of 5 weeks of chronic UVB and
then no UVB for 3 weeks (Method 4), mouse groups had the same number of LC
for 5 weeks of chronic UVB exposure, but after 3 weeks of no UVB and LC
depletion by DT injections Lang-DTR mice had a decreased number of clones.
This suggests that either the presence of LC still promotes clonal expansion even
without UVB exposure, or LC presence prevents clonal regression. Further
studies need to be done, preferably by manually counting the cells per clone.
It is possible that LC may be mediating apoptosis directly or indirectly via
immune regulation cells that mediate apoptosis, which in turn affect clonal
expansion and regression. UV-induced immunosuppression is mediated via the
FasL/FasR apoptosis mediator system and abrogating keratinocyte apoptosis
prevents UV-induced immune tolerance (182). Schwarz and colleagues reported
that the ablation of LC in their UVR study failed to produce immune tolerance via
T regs, which are known to secrete IL-10 on hapten-specific stimulation
(101,177) and may use the apoptosis-related FasL/FasR-ligand system.
Moreover, as mentioned earlier in the introduction, apoptosis links both chemical
and UVR-induced carcinogenesis, as it is related to reactive oxygen species and
Ras-induced p53 mediated apoptosis (87,88), both of which may be related to
NADPH-oxidase of neutrophils, UVB-induced ROS production and apoptosis
(89).
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LC may also be using apoptosing keratinocytes to influence the immune

system. Viable, but functionally impaired (by UVR) LC that have engulfed
apoptotic or photodamaged particles, have the potential to cause tolerance of
premalignant lesions. Evidence of delay in LC apoptosis after acute UVR (193)
(providing the necessary time to CPD-positive LC to successfully reach draining
LN to localize to T cell areas in the inner cortex of the LN, as opposed to their
dDC counterpart that localize to B cell areas), supports even further LC role in
possible immune regulation of altered self-antigens. Alternatively, LC may
themselves indirectly promote regulatory T cell generation by undergoing
apoptosis to distribute peripheral ‘‘altered self’’ antigens to resident CD8α+ DC,
which have been shown to induce tolerance (194,195).
Another way in which LC may be mediating immune response may be via
their interaction with another dendritic population of γδ T cells, also called
dendritic epidermal T cells (DETC), which are present in murine (and other
mammals, but not human) skin (196). DETC have been shown to cause specific
immunologic tolerance in vivo by inhibiting proliferation, via a cytotoxic
mechanism, of naïve T cells in response to hapten-bearing dendritic cells in vitro
(197). LC and γδ DETC are in contact with the renewing basal keratinocytes, the
main cells involved in carcinogenic transformation. Moreover, after specific
epidermal stimuli, LC and γδ DETC cell bodies have been shown to become
juxtaposed (80). Although some studies have found that DETC were absent
during the development of ultraviolet radiation (UVR)-induced skin cancers,
consistent with the possibility that this may result in impaired host anti-tumor
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immunity (198) our studies have shown that GL3+ DETC numbers are reduced,
but are still present after chronic UVB exposure. Thus, it is possible that LC can
interact with DETC to induce tolerance (perhaps via a cytotoxic mechanism) to
inhibit proliferation of naïve T cells (197). It would be interesting to study the
influence of Langerhans cells on clonal numbers in T cell depleted mouse strains
after acute and chronic UVB exposure.
LC have been shown to react to NKG2D-ligand upregulation by
keratinocytes in situations of environmental stress and cell damage, with recent
evidence showing that LC serve as immunoregulatory cells by activating natural
killer (NK) T cells (199). Interestingly, in regard to UVB-studies, Brash and
colleagues demonstrated that antigen-specific immunity does not mediate acute
regression of UVB-induced p53-mutant clones in immunodeficiency mice that still
contained NKT cells (108). This raises the possibility that, in our clonal
regression studies, LC induction of tolerance may be mediated via NKT cells. It is
also possible that LC may be promoting carcinogenesis by stimulating a recently
identified and characterized tumor-promoting CD8+ T cell population (200,201).
Moreover, recent finding of tumor associated macrophages (TAMs) that are
involved in tumor initiation, promotion and immune suppression (202), raises the
possibility that LC may act in a similar fashion.
Recently, Loser et al. demonstrated that the capacity to induce T reg cells
was dependent on receptor activator of NF-κB (RANK) activation on epidermal
LC by interaction with its ligand (RANKL, also known as CD254, OPGL and
TRANCE) on keratinocytes (203). They reported that RANKL is expressed in
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keratinocytes of the inflamed skin and its overexpression resulted in functional
alterations of epidermal dendritic cells and systemic increases of regulatory
CD4+CD25+ T cells. Because RANK-activated LC have demonstrated potent T
reg cell activation in vitro, it is possible that UV- damaged RANK-activated LC
may similarly activate T reg cells directly, once they reach the draining LN.
LC effect on other immune cells most likely depends on the cytokine
milieu, and thus the maturity state of LC, which in turn create a pro-or antitumorigenic microenvironment. Lower levels of TNF and MIP3α (both associated
with tumor regression) within the microenvironment induced correlated with
increased levels of immature LC, which had decreased production of IL-2 and
increased production of immunosuppressive IL-10 (73,204). The increased
presence of immature LC in cervical intraepithelial neoplasia is thought to be
responsible for deficient presentation of alloantigen to T cells (74). It is quite
possible that chronic inflammation of chemical carcinogenesis or immune
suppression of chronic UVR exposure maintain a population of immature LC,
which create a tolerogenic state either by presentation of tumor antigens without
co-stimulatory molecules required for T cell activation, or by stimulating other
tolerogenic cells.
Our understanding of Langerhans cells’ role in modulating the immune
response in the direction of immunity or tolerance has been a hot topic of
discussion and continues to evolve. With recent advances in LC ablating models,
photoimmunology and cell identification, as well as continuous development of
transgenic mouse models inducing and/or abrogating pro-apoptotic or pro-
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survival regulators, we come closer to gaining insight into Langerhans cell
influence in cutaneous responses to chemical and UVR carcinogenesis. A better
understanding of the molecular and cellular mechanisms of DC (and specifically
LC) function may open the door to future therapies in fighting skin and other
cancers. Some therapies are already currently under way, from using
differentiated DC in extracorporeal photochemotherapy in CTCL treatment (205),
to exploiting the potent antigen-presenting function of LC with the right
stimulation in epicutaneous immunization (206). At this point, other therapies are
still only hypothetical, such as mediating Langerhans cells’ recently discovered
immune suppression functions (199,203) by targeting or blocking their RANKRANKL interaction or NKT cell activation.
In conclusion, LC exert diverse and measurable influences on epidermal
proliferative responses to both chemical and UVB exposures in a transgenic
murine mouse model. In our laboratory we showed that LC presence in the skin
is associated with increased epidermal proliferation and hypertrophy after
exposure to a mutagen and/or a tumor promoter. This points to tumor initiation
and/or to tumor promotion as being two potential mechanisms of by which LC
may induce increased tumor formation after chemical carcinogenesis. In UVB
studies, LC presence was found to be associated with increased keratinocyte
apoptosis levels after acute UVB exposure, which parallels with our findings of
increased numbers of premalignant lesions after chronic UVB treatment in LC
intact mice. Moreover, we found that when we exogenously induce depletion of
LC after chronic UVB exposure, we see more acute regression of premalignant
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mutant clones after several weeks. These preliminary findings reinforce the
fundamental role of LC in processes involved in cancer formation. It will be
exciting to follow up on these findings with repeat experiments in both chemical
and UVB models.
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FIGURES

Figure 1 a-b: (DMBA+TPA) After two-stage chemical carcinogenesis (DMBA
+TPA), there was significantly smaller increase in epidermal proliferation
and epidermal thickness in Lang-DTA mice.

Figures 1a and 1b show Lang-DTA mice displaying less keratinocyte proliferation
and epidermal hyperthrophy versus NLC. Figure 1a shows at baseline Lang-DTA
and NLC mouse skin showed comparable epidermal thickness (7.9 ± 1.8 vs 6.9 ±
2.8 µm, P=NS) and proliferation rates as measured by Ki-67
immunohistochemistry (IHC) (13.6 ± 2.6 vs 12.7 ± 2.8 # Ki-67+ cells, P=NS). After
a single application of mutagen DMBA, followed by repeated promoter TPA (x 5.5
wks), Lang-DTA skin showed substantially smaller increases in epidermal
thickness (25.8 ± 8.9 vs 59.2 ± 28.4 µm, P<0.0001) and proliferation (25.7 ± 7.4
vs 31.5 ± 7.7 # Ki-67+ cells, P=0.007) as compared to NLC (Figure 1b).
	
  
Figure 2: Epidermal sections of Lang –DTA (top) and NLC (bottom) mouse
skin, stained with Ki-67 by immunohistochemistry (brown).

stratum granulare
stratum basale
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Figure 3 a-d: (TPA alone, 4 weeks) After 4 weeks of TPA application, there
was significantly smaller increase in epidermal proliferation and epidermal
thickness in Lang-DTA mice vs NLC. After repeated applications of tumor
promoter TPA (x 4 wks), LC-depleted (Lang-DTA) skin showed a smaller
increase in epidermal proliferation (16.7 ± 0.4 vs 19.3 ±0.5 # Ki-67+cells,
P=0.0002, Figure 3a) and minimal epidermal thickness (5.1 ± 0.1 vs 8.5 ± 0.2
µm, P<0.0001, Figure 3c), as compared to NLC mice. Statistical significant was
reached for means per mouse for epidermal hypertrophy (P=0.0037, Figure 3d),
but not for epidermal proliferation (P= NS, 0.3982, Figure 3b).
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Figure 4 a-d: (DMBA alone) After 8 doses of mutagen (DMBA alone)
treatment every two weeks, there was a significantly smaller increase in
epidermal proliferation and epidermal thickness in Lang-DTA mice vs NLC
mice. After repeated applications of mutagen DMBA alone, Lang-DTA skin
showed a smaller increase in epidermal proliferation (12.8 ± 0.99 vs 22.7 ± 1.4 #
Ki-67+cells, P=0.0001, Figure 4a) and minimal epidermal thickness (14.4 ± 1.08
vs 17.8 ± 1.0 µm, P<0.0292, Figure 4c), as compared to NLC skin. Figures 4b
and 4d show corresponding data per mouse. Skin harvested was paratumoral.
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Figure 5 a-c (Acute UVB1): Cleaved caspase-3 by IHC. After a single dose
of UVB (3,360 J/m2) there was a significantly smaller number of apoptotic cells
in the epidermis of Lang-DTA versus NLC mice. LC-deficient skin (Lang-DTA),
as compared to skin of LC-intact normal littermate controls (NLC), showed
less epidermal apoptosis after acute UVB irradiation, as measured by IHC
(21.4 ± 1.1 vs 26.4 ± 1 # cleaved caspase-3+ cells, P=0.0099, Figure 5a).
Figure 5c shows representative cleaved caspase-3 IHC stained sections for
corresponding mouse groups.
	
  

	
  
	
  
	
  
	
  
	
  
Figure 5c
Lang-DTA Non-irradiated anterior belly skin

NLC Non-irradiated anterior belly skin

Lang-DTA UVB-exposed dorsal skin

NLC UVB-exposed dorsal skin
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Figure 6 a-c: (Acute UVB1) Sunburn cells on H&E. LC-deficient skin (LangDTA), as compared to skin of LC-intact normal littermate controls (NLC), showed
less epidermal apoptosis after a single dose of acute UVB irradiation
(3,360J/m2), as measured by on H&E (9.3 ± 0.5 vs 13.9 ± 1.5 # sunburn cells, P=
0.0069, Figure 6a) in the pilot acute UVB experiment (n=3). Mean per mouse did
not reach statistical significance (Figure 6b). Figure 6c shows examples of
sunburn cells, with pyknotic nuclei and eosinophilic cytoplasm, on H&E sections.

Figure 6c: Sunburn cells
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Figure 7 a-b: Raw Data for cleaved caspase-3 after acute UVB exposure.
Figure 7a shows cleaved caspase-3 data for pilot experiment (n=3) per each
strip 1-3, where strip 2 corresponds to the middle dorsal treated skin, and strips
1 and 3 are side strips. Of note, previously shown data in Figures 6 are from
middle strips (i.e. strip 2 from each mouse). Figure 7b contains all the cleaved
caspase-3 data for both pilot or ‘Old Experiment Data’ as parked in graph (n=3)
and repeated experiment (n=7).
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Figure 8 a-b: Cleaved caspase-3 after acute UVB-exposure. Combined
data from pilot and repeated experiment.
Figure 8a contains combined apoptosis data from pilot acute UVB experiment
(n=3) and repeated (n=7) experiment measuring cleaved caspase-3 for LangDTA vs NLC irradiated skin. There was a statistically significant difference in
epidermal apoptosis (18.9 ± 0.4 vs 21.1 ± 0.4 # cleaved caspase-3+ cells, P<
0.0001). At baseline (Figure 8a), non-irradiated anterior belly skin showed no
difference in apoptosis in Lang-DTA vs NLC skin (0.01 ± 0.0 vs 0.01 ± 0.0 #
cleaved caspase-3+ cells, P= NS, 0.3692).
Figure 8b represents the means per mouse combined apoptosis data from the
pilot acute UVB experiment (n=3) and repeated (n=7) experiment measuring
cleaved caspase-3 for Lang-DTA vs NLC irradiated skin. Statistical
significance was not reached for the means per mouse (19.77 ± 1.7 vs 22.7 ±
2.1 # cleaved caspase-3+ cells, P= NS, 0.2877).
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Figure 9 a-c: Acute UVB Sheets Pilot experiment. Co-staining langerin
(green) and cleaved caspase-3 (blue) on epidermal sheets by
immunofluorescence in NLC Mice, after acute dose of UVB (3,360 J/m2).
Magnification 25x.
Figure 9a – NLC Acute UVB (caspase-3 and langerin)

Figure 9b – NLC Acute UVB (caspase-3)

Figure 9c – NLC Acute UVB (langerin)
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Figure 10 a-c: Acute UVB Sheets1: Pilot experiment. Co-staining langerin
(green) and cleaved caspase-3 (blue) on epidermal sheets by
immunofluorescence in NLC Mice, after acute dose of UVB (3,360 J/m2).
Magnification 63x.
Figure 10a – NLC Acute UVB (caspase-3 and langerin)

	
  
	
  
Figure 10b – NLC Acute UVB (caspase-3)	
  

	
  	
  
	
  
Figure 10c – NLC Acute UVB (langerin)	
  

	
  

	
  

	
  

112	
  
Figure 11 a-c: Acute UVB Sheets1: Pilot experiment. Co-staining langerin
(green) and cleaved caspase-3 (blue) on epidermal sheets by
immunofluorescence in Lang-DTR mice, after acute dose of UVB (3,360 J/m2).
Magnification 25x.
Figure 11a – Lang-DTR Acute UVB (caspase-3 and langerin)

Figure11b – Lang-DTR Acute UVB (caspase-3)

Figure 11c – Lang-DTR Acute UVB (langerin)
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Figure 12 a-c: Acute UVB Sheets1: Pilot experiment. Co-staining langerin
(green) and cleaved caspase-3 (blue) on epidermal sheets by
immunofluorescence in Lang-DTR mice, after acute dose of UVB (3,360 J/m2).
Magnification 63x.
Figure 12a – Lang-DTR Acute UVB (caspase-3 and langerin)

Figure 12b – Lang-DTR Acute UVB (caspase-3)

Figure 12c – Lang-DTR Acute UVB (langerin)

	
  

	
  

114	
  
Figure 13 a-b: Acute UVB Sheets2. Co-staining langerin (green) and cleaved
caspase-3 (blue) on epidermal sheets by immunofluorescence in NLC and
Lang-DTR dorsal skin, after acute dose of UVB (3,360 J/m2). Magnification
25x.
Figure 13a (panels 1-6): NLC Dorsal Skin (UVB Exposed).
1
2
3

4
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6

Figure 13b (panels 1-6): Lang-DTR Dorsal Skin (UVB Exposed)
1
2
3

4
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Figure 14 a-c: Acute UVB Sheets2. Co-staining langerin (green) and cleaved
caspase-3 (blue) on epidermal sheets by immunofluorescence in NLC and LangDTR unexposed anterior belly skin. Figures 14c are antibody controls after acute
dose of UVB (3,360 J/m2). Magnification 25x.
Figure 14 a (panels 1-3): Anterior Belly (NLC)
1
2

3

Figure 14b (panels 1-3): Anterior Belly (Lang-DTR)
1
2

3

Figure 14c (panels 1-2): IgG Control for Cleaved caspase-3 (green) and
langerin/CD207 (blue)
1 – Dosal skin
2 – Dorsal skin
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Figure 15 a-c: (Chronic UVB0, IHC) After chronic UVB exposure, NLC
mouse skin contains p53-mutant clones and viable langerin+ DC by
immunohistochemistry. Figure Va shows p-53 mutant clones stained by IHC
on epidermal sheets (CM5+, brown) after 3 weeks of chronic UVB. Figure 15b
shows a larger p53-mutant clone after 5 weeks (courtesy of Wengeng Zhang).
Figure 15c shows langerin+ DC (langerin/CD 207+, brown) after 3 weeks of
chronic UVB.
Figure 15a

Figure 15b

Figure 15c
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Figure 16 a-b: After chronic UVB exposure, NLC mouse skin shows
viable langerin+ DC that co-stain with mutated p53-clones by
immunofluorescence. Confocal microscopy reveals langerin+ DC (CD207+,
blue) coincident with mutant p53 clones (CM5, green) after 9 weeks of UVB,
Figure 16a. 3-D view of LC and mutant clones, Figure 16b.
Figure 16a

Figure 16b
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Figure 17 a-b: Method 1 - 9 Weeks (Chronic UVB1, n=3, IF). After 9 weeks
of chronic UVB exposure, Lang-DTA mouse skin compared to NLC had a
smaller number of mutated clones per mm2 (8.0 ± 1.1 vs 15.4 ± 2.3, P<0.004,
Figure 17a). Statistical significance was not reached for means per mouse
(10.7 ± 2.2 vs 16.9 ± 4.2, P= NS, 0.2636, Figure 17c). Figure 17b shows data
per HPF per mouse.
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Figure 18 a-b: Method 2 - 9 Weeks (Chronic UVB1, n=4, IF). After 9 weeks
of chronic UVB exposure, there is a trend toward Lang-DTA mouse skin vs
NLC having a smaller number of mutated clones per mm2 (1.7 ± 0.3 vs 2.5 ±
0.5 # mutated clones/mm2, P= NS, 0.1636, Figure 18a), which did not reach
statistical significance. Means per mouse also did not reach statistical
significance (1.7 ± 0.3 vs 2.4 ± 0.7 mean # mutated islands/mm2, P= (NS)
0.3528).
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Figure 19 a-b: Method 3 - 5 Weeks (Chronic UVB2, n=8 and 7, IF). After 5
weeks of chronic UVB exposure, Lang-DTA mouse skin compared to NLC had
a smaller number of mutated clones per mm2 (0.9 ± 0.05 vs 1.0 ± 0.1 # mutant
clones/mm2, P=0.0489, Figure 19a). Statistical significance was not reached
for means per mouse (0.9 ± 0.1 vs 1.1 ± 0.2, P= NS, 0.3797, Figure 19b).
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Figure 20 a-b: Method 4 - 5 weeks UVB and 3 weeks regression (Chronic
UVB3, n=8, IF): (Lang-DTR vs NLC). After 5 weeks of chronic UVB followed
by 3 weeks of no UVB, there was a statistically significant smaller number of
mutant clones per mm2 in Lang-DTA versus NLC mice (0.2 ± 0.0 vs 0.4 ± 0.0,
P≤ 0.0001, Figure 20a). Statistical significance was also reached for mean
number of mutated clones/mm2 per mouse in Lang-DTA vs NLC (0.2 ± 0.0 vs
0.4 ± 0.0, P=0.0106, Figure 20b).
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Figure 21 a-b: Summary of Chronic UVB methods. Y-axis corresponds to
duration of chronic UVB irradiation. Method 1 and 2 correspond to 9 weeks of
chronic UVB, with number of clones counted by different methods. Method 3
corresponds to 5 weeks of chronic UVB in Lang-DTA vs NLC mice. Method 4
corresponds to 5 weeks of chronic UVB with 3 weeks of no UVB time in LangDTR vs NLC mice. There is a discrepancy in the number of clones per mm2 in
Method 1 versus Method 2 at 9 weeks of chronic UVB, with the former being
approximately 5-6 times greater (represented visually in Figure 21a and Figure
21b, below), which may be explained by the method of clone counting and
resolution used to capture images.
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Figure 22 a-f: Area/Mutant Clone in Chronic UVB. Method 1, 3 and 4
correspond to data gathered after chronic UVB for 9 weeks, 5 weeks, and 5
weeks with no UVB for 3 weeks, respectively. Figures 22 d-f below are the
corresponding means per mouse for each method.
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Figure 23 a-c: Mutant Clone Area in Lang-DTA vs NLC Mice by Bins. Bins
assigned as multiples of EPUs (16 cells or keratinocytes). Method 1, 3 and 4
correspond to data gathered after chronic UVB for 9 weeks, 5 weeks and 5 weeks
with no UVB for 3 weeks, respectively.
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Figure 24: Mutant Clone Bins as described by Zhang et al.
(Carcinogenesis 2005).
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Figure 25: Langerin+ DC Within or Around Mutant Clones in Lang DTA
and Lang-DTR mice after Chronic UVB.
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Figure 26 a-b: Number Replacement (langerin+ DC) LC in Lang-DTA
versus NLC after 5 weeks of chronic UVB. (Data not analyzed from
unirradiated dorsal skin).
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Figure 27 a-e: LC Density Associated with Mutant Clones in Lang-DTA mice
(n=7) and NLC (n=6) after 5 weeks of Chronic UVB.

Figure 27e – Langerin+ (blue) DC around clone (green)
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Figures 28 a-e: Mutant Clone Morphology. Epidermal proliferating units
(EPUs) expand into clonal islands.
Figure 28a

Figure 28b

Figure 28d

Figure 28e

	
  

Figure 28c
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Figure 29 a-f: DETC and LC in Lang-DTA Mice: Sparse GL3-Positive
DETCs were present after 5 weeks of chronic UVB exposure and some
were seen interacting with langerin+ DC. Figures 29 a & b show DETC
(GL3+, red) interacting with langerin+ DC (CD207+, blue), next to mutant clone
(CM5+, green) in Lang-DTA mouse skin. Figure 29b is a close up of DETC and
LC interaction. Figure 29c shows that there is no significant relationship
between GL3+ cell density and presence of clones after 5 weeks of chronic
UVB. Many GL3+ cells were located within or near hair follicles, as show in
Figures 29d and 29e. Figure 29f is anterior belly control in Lang-DTA mouse
skin (non-irradiated).
Figures 29 a&b: GL3+ and langerin+ DC interaction, with zoomed-in image
on right.

Figure 29c

Fig 29d-UVB exposed

	
  

Fig 29e- UVB exposed

Fig 29f – Anterior belly
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Figure 30 a-e: DETC and LC in NLC Mice: Sparse GL3-Positive DETCs were
present after chronic UVB exposure and some were seen interacting with
langerin+ DC. Figures 30 a-d are of NLC mouse skin, showing DETC (GL3+, red)
interacting with langerin+ DC (CD207+, blue). Figures 30b and 30c are different
planes of same image, the latter with a scattered clone in background (CM5+,
green). Figure 30e is anterior belly control for NLC (non-irradiated). Many GL3+
cells were located within or near hair follicles, as seen in Figures 30 b-d.
Figure 30a

Figure 30b

Figure 30d

Figure 30e- Anterior belly

	
  
	
  

Figure 30c

